

# NHS Greater Glasgow and Clyde: New Medicines Decisions

## January 2016 to present

In Scotland, a newly licensed medicine is routinely available in a health board only after it has been:

- accepted for use in NHS Scotland by the Scottish Medicines Consortium (SMC), and
- accepted for use by the health board's Area Drug and Therapeutics Committee (ADTC).

All medicines accepted by SMC are available in Scotland, but may not be considered 'routinely available' within NHS Greater Glasgow and Clyde (NHSGG&C) because of available services and preferences.

'Routinely available' means that a medicine can be prescribed by the appropriately qualified person within a health board.

Each health board has an ADTC. The Greater Glasgow and Clyde ADTC is responsible for advising the NHSGG&C health board on all aspects of the use of medicines.

Medicines routinely available within NHSGG&C are usually included in the GGC Formulary. The Formulary is a list of medicines for use in the health board that has been agreed by ADTC in consultation with healthcare professionals to prescribe for common medical conditions. The GGC Formulary can help improve safety as prescribers are likely to become more familiar with the medicines included and are consistent across the health board.

### How does NHSGG&C decide which new medicines to make routinely available for patients?

The ADTC in NHSGG&C will consider national and local guidance before deciding whether to make a new medicine routinely available.

### What national guidance does the ADTC consider?

- SMC advice: The SMC considers newly licensed medicines and advises health boards in Scotland whether they should be available. When SMC considers a new medicine for the NHS in Scotland
  - how well the medicine works,
  - which patients might benefit from it,
  - whether it is as good or better than medicines the NHS already uses to treat the medical condition, and
  - whether it is good value for money.
- In the table below, national guidance usually refers to SMC advice. Links to SMC advice for individual medicines are also included in the table.
- In some cases, other agencies may also provide guidance on how medicines should be used. For example, Healthcare Improvement Scotland issues alerts to advise if National Institute for Health and Care Excellence (NICE) Medicines Technology Appraisals (NICE MTAs) are applicable in Scotland.

### What local guidance does the ADTC consider?

- Advice from local clinical experts who would be expected to prescribe a particular medicine, where that service is available in NHSGG&C.

### Why is a particular medicine not routinely available in NHSGG&C?

- This is usually because the medicine is not recommended for use in NHS Scotland by the SMC.
- The medicine may not be routinely available in a health board, particularly in smaller health boards, because there is not a suitable specialist who may use the medicine.

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>5-aminolaevulinic acid</b> topical gel Ameluz® 1260/17	Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults.  <a href="http://www.scottishmedicines.org.uk/files/advice/5-aminolaevulinic_acid_Ameluz_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/5-aminolaevulinic_acid_Ameluz_FINAL_July_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>5-aminolaevulinic acid (as hydrochloride)</b> gel Ameluz® 1260/17	Treatment of superficial and / or nodular basal cell carcinoma (BCC) unsuitable for surgical treatment due to possible treatment-related morbidity and / or poor cosmetic outcome in adults.  <a href="http://www.scottishmedicines.org.uk/files/advice/5-aminolaevulinic_acid_Ameluz_Resubmission_FINAL_Jan_0218_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/5-aminolaevulinic_acid_Ameluz_Resubmission_FINAL_Jan_0218_for_website.pdf</a>	Routinely available in line with national guidance	26/02/2018
<b>Abatacept</b> infusion, injection Orencia® 1287/17	Alone or in combination with methotrexate for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy including methotrexate has been inadequate, and for whom additional systemic therapy for psoriatic skin lesions is not required.	Not routinely available as not recommended for use in NHSScotland	11/12/2017
<b>Abatacept</b> injection Orencia® 1230/17	Treatment of highly active and progressive disease in adult patients with rheumatoid arthritis not previously treated with methotrexate.	Not routinely available as not recommended for use in NHSScotland	24/04/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Abatacept, Adalimumab, Etanercept, Tocilizumab</b>	Juvenile idiopathic arthritis - various licences with differing age limits	Routinely available in line with national guidance	22/02/2016
TA373			
<b>Abemaciclib</b> tablets Verzenios® SMC2135	Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor* as initial endocrine-based therapy, or in women who have received prior endocrine therapy.	Routinely available in line with local or regional guidance	10/06/2019
<b>Abemaciclib</b> tablets Verzenios® SMC2179	Treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy or in women who have received prior endocrine therapy.	Routinely available in line with local or regional guidance	10/06/2019
<b>Abiraterone acetate</b> tablets Zytiga® SMC2215	Abiraterone acetate with prednisone or prednisolone for the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer in adult men in combination with androgen deprivation therapy.	Routinely available in line with local or regional guidance	24/02/2020

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Adalimumab</b> sub-cutaneous injection Humira® 1173/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1173_16_adalimumab_Humira/adalimumab_Humira">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1173_16_adalimumab_Humira/adalimumab_Humira</a>	Treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08).	Not routinely available as not recommended for use in NHSScotland	22/08/2016
<b>Adalimumab</b> injection Humira® 1208/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1208_16_adalimumab_Humira/adalimumab_Humira_Non-submission</a>	Treatment of moderately active Crohn's disease in paediatric patients (from 6 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy and a corticosteroid and/or an immunomodulator, or who are intolerant to or have contraindications for such therapies	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Adalimumab</b> injection Humira® 1243/17  <a href="http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Abbreviated_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Abbreviated_FINAL_May_2017_for_website.pdf</a>	Treatment of active moderate to severe hidradenitissuppurativa (HS) (acne inversa) in adolescents from 12 years of age with an inadequate response to conventional systemic HS therapy.	Routinely available in line with national guidance	23/10/2017
<b>Adalimumab</b> injection Humira® 1209/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1209_16_adalimumab_Humira/adalimumab_Humira_Non_submission</a>	Treatment of non-infectious intermediate, posterior and panuveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid-sparing, or in whom corticosteroid treatment is inappropriate.	Not routinely available as not recommended for use in NHSScotland	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Adalimumab</b> subcutaneous injection Humira® 1305/18	Treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom conventional therapy is inappropriate.  <a href="http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/adalimumab_Humira_Non_Sub_FINAL_Dec_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	26/02/2018
<b>Adalimumab</b> injection Humira® 1143/16	Treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa) in adult patients with an inadequate response to conventional systemic HS therapy.	Routinely available in line with national guidance	13/06/2016
<b>Adalimumab, dexamethasone intravitreal implant</b>  MTA 460	Non-infectious uveitis  <a href="https://www.nice.org.uk/Guidance/TA460">https://www.nice.org.uk/Guidance/TA460</a>	Routinely available in line with national guidance	23/10/2017
<b>Adalimumab, Etanercept, Ustekinumab</b>  MTA 455	plaque psoriasis in children and young people  <a href="https://www.nice.org.uk/guidance/ta455/resources/adalimumab-etanercept-and-ustekinumab-for-treating-plaque-psoriasis-in-children-and-young-p">https://www.nice.org.uk/guidance/ta455/resources/adalimumab-etanercept-and-ustekinumab-for-treating-plaque-psoriasis-in-children-and-young-p</a>	Routinely available in line with national guidance	23/10/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Afatinib</b> tablets Giotrif® 1174/16	As monotherapy for the treatment of locally advanced or metastatic non small cell lung cancer of squamous histology progressing on or after platinum-based chemotherapy.	Not routinely available as not recommended for use in NHSScotland	22/08/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1174_16_afatinib_Giotrif/afatinib_Giotrif">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1174_16_afatinib_Giotrif/afatinib_Giotrif</a>		
<b>Aflibercept</b> injection Eylea® 1186/16	For adults for the treatment of visual impairment due to myopic choroidal neovascularisation (myopic CNV).	Routinely available in line with national guidance	10/10/2016
	<a href="http://www.scottishmedicines.org.uk/files/advice/aflibercept_Eylea_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/aflibercept_Eylea_FINAL_Sept_2016_for_website.pdf</a>		
<b>Albiglutide</b> pre-filled pen Eperzan® 1024/15	Treatment of type 2 diabetes mellitus in adults to improve glycaemic control in combination with other glucose-lowering medicinal products including basal insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.	Routinely available in line with national guidance	22/02/2016
<b>Alectinib</b> capsules Alecensa® 2012	As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).	Routinely available in line with local or regional guidance	13/08/2018
	<a href="https://www.scottishmedicines.org.uk/media/3645/alectinib-hydrochloride-alecensa-final-july-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3645/alectinib-hydrochloride-alecensa-final-july-2018-for-website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Alectinib hydrochloride</b> capsules Alecensa® 1257/17	As monotherapy for the treatment of adult patients with anaplastic lymphoma kinase positive advanced non-small cell lung cancer previously treated with crizotinib.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1257_17_alectinib_hydrochloride_Alecensa/alectinib_hydrochloride_Alecensa_Non_Sub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1257_17_alectinib_hydrochloride_Alecensa/alectinib_hydrochloride_Alecensa_Non_Sub</a>	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Alendronic acid</b> effervescent tablet Binosto® 1137/16	Treatment of postmenopausal osteoporosis.	Routinely available in line with national guidance	18/04/2016
<b>Alimemazine</b> tablets, syrup	Sedative antihistamine	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	23/10/2017
<b>Alirocumab</b> pre-filled pen Praluent® 1147/16	adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet in combination with a statin or statin with other lipid lowering therapies in patients unable to reach LDL-C goals with the maximum tolerated dose of a statin or, alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1147_16_alirocumab_Praluent/alirocumab_Praluent</a>	Routinely available in line with local or regional guidance  10/10/2016	12/12/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Alirocumab</b> injection <b>Praluent®</b> SMC2201</p>	<p>In adults with established atherosclerotic cardiovascular disease to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: - in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, alone - or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>10/06/2019</p>
<p><b>Anakinra</b> injection in pre-filled syringe <b>Kineret®</b> SMC2104</p>	<p>In adults, adolescents, children and infants aged eight months and older with a body weight of 10kg or above for the treatment of Still's disease, including Systemic Juvenile Idiopathic Arthritis (SJIA) and Adult-Onset Still's Disease (AOSD), with active systemic features of moderate to high disease activity, or in patients with continued disease activity after treatment with non-steroidal anti-inflammatory drugs (NSAIDs) or glucocorticoids. Anakinra can be given as monotherapy or in combination with other anti-inflammatory drugs and disease-modifying anti-rheumatic drugs (DMARDs).</p>	<p>Routinely available in line with national guidance</p>	<p>08/10/2018</p>
<p><b>Apalutamide</b> tablets <b>Erleada®</b> SMC2268</p>	<p>In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC) who are at high risk of developing metastatic disease.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>24/02/2020</p>



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Aprepitant</b> capsules, powder for oral suspension  <b>Emend®</b>  1241/17	As part of combination therapy, for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy in infants, toddlers and children from the age of six months to less than 12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules). Aprepitant is given as part of combination therapy  <a href="http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_FINAL_May_2017_Amended_060617_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_FINAL_May_2017_Amended_060617_for_website.pdf</a>	Routinely available in line with local or regional guidance	23/10/2017
<b>Aprepitant</b> capsules, suspension  <b>Emend</b>  1252/17	As part of combination therapy, for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy in children, toddlers and infants from the age of six months to <12 years (powder for oral suspension) and adolescents from the age of 12 years to 17 years (hard capsules).  <a href="http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/aprepitant_Emend_Abbreviated_FINAL_June_2017_for_website.pdf</a>	Routinely available in line with local or regional guidance	23/10/2017
<b>Arsenic trioxide</b> infusion  <b>Trisenox®</b>  SMC2025	In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count, $\leq 10 \times 10^3/\mu\text{l}$ ), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.	Not routinely available as not recommended for use in NHSScotland	25/02/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Arsenic trioxide</b> infusion Trisenox® SMC2181	In combination with all-trans-retinoic acid (ATRA [tretinoin]) for the induction of remission, and consolidation in adult patients with newly diagnosed, low-to-intermediate risk acute promyelocytic leukaemia (APL) (white blood cell count $\leq 10 \times 10^3/\mu\text{l}$ ), characterised by the presence of the t(15;17) translocation and/or the presence of the Pro Myelocytic Leukaemia/Retinoic-Acid-Receptor-alpha (PML/RAR-alpha) gene.	Routinely available in line with local or regional guidance	12/08/2019
<b>Asparaginase (Recombinant E.coli asparaginase)</b> infusion Spectrila® 1319/18	As a component of antineoplastic combination therapy for the treatment of acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years and adults.  <a href="https://www.scottishmedicines.org.uk/medicines-advice/asparaginase-spectrila-abbreviatedsubmission-131918/">https://www.scottishmedicines.org.uk/medicines-advice/asparaginase-spectrila-abbreviatedsubmission-131918/</a>	Routinely available in line with local or regional guidance	23/04/2018
<b>Ataluren</b> oral suspension Translarna® 1131/16	Treatment of Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Not routinely available as not recommended for use in NHSScotland	18/04/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Atezolizumab</b> infusion <b>Tecentriq®</b> 1336/18	As monotherapy for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy. Patients with epidermal growth factor receptor (EGFR) activating mutations or anaplastic lymphoma kinase (ALK)-positive tumour mutations should also have received targeted therapy before receiving atezolizumab.  <a href="https://www.scottishmedicines.org.uk/media/3554/atezolizumab-tecentriq-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3554/atezolizumab-tecentriq-final-june-2018-for-website.pdf</a>	Routinely available in line with local or regional guidance	13/08/2018
<b>Atezolizumab</b> infusion <b>Tecentriq®</b> SMC2208	In combination with bevacizumab, paclitaxel and carboplatin, for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC). In patients with epidermal growth factor receptor (EGFR) mutant or anaplastic lymphoma kinase (ALK)-positive NSCLC, atezolizumab in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.	Not routinely available as not recommended for use in NHSScotland	09/12/2019
<b>Atezolizumab</b> infusion <b>Tecentriq</b> SMC2103	As monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy.	Not routinely available as not recommended for use in NHSScotland	10/12/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Atezolizumab</b> infusion Tecentriq® SMC2254	In combination with nab-paclitaxel and carboplatin for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (NSCLC) who do not have EGFR mutant or ALK-positive NSCLC.	Not routinely available as not recommended for use in NHSScotland	09/12/2019
<b>Atezolizumab</b> infusion Tecentriq® 1297/18	Monotherapy for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma after prior platinum-containing chemotherapy or who are considered cisplatin ineligible.  <a href="https://www.scottishmedicines.org.uk/medicines-advice/atezolizumab-tecentriq-fullsubmission-129718/">https://www.scottishmedicines.org.uk/medicines-advice/atezolizumab-tecentriq-fullsubmission-129718/</a>	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<b>Avelumab</b> infusion Bavencio® 1315/18	As monotherapy for the treatment of adult patients with metastatic Merkel cell carcinoma (mMCC).	Routinely available in line with local or regional guidance	11/06/2018
<b>Aviptadil with Phentolamine</b> intracavernous injection Invicorp® 1284/17	For the symptomatic treatment of erectile dysfunction in adult males due to neurogenic, vasculogenic, psychogenic, or mixed aetiology.	Routinely available in line with national guidance	11/12/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Axicabtagene ciloleucel</b> infusion <b>Yescarta®</b> SMC2114	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	Not routinely available as not recommended for use in NHSScotland	25/02/2019
<b>Axicabtagene ciloleucel</b> infusion <b>Yescarta®</b> SMC2189	Treatment of adult patients with relapsed or refractory diffuse large B cell lymphoma (DLBCL) and primary mediastinal large B cell lymphoma (PMBCL), after two or more lines of systemic therapy.	Routinely available in line with local or regional guidance	07/10/2019
<b>Azacitidine</b> injection <b>Vidaza®</b> 1175/16	Treatment of adult patients aged 65 years or older who are not eligible for haematopoietic stem cell transplantation (HSCT) with acute myeloid leukaemia (AML) with >30% marrow blasts according to the World Health Organisation (WHO) classification.	Not routinely available as not recommended for use in NHSScotland	22/08/2016
<b>Baricitinib</b> tablets <b>Olumiant®</b> 1265/17	Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  16/04/2017	23/10/2017
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1175_16_azacitidine_Vidaza/azacitidine_Vidaza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1175_16_azacitidine_Vidaza/azacitidine_Vidaza</a>  <a href="http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Baricitinib</b> tablets <b>Olumiant®</b> 1265/17	Treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricitinib may be used as monotherapy or in combination with methotrexate.	Routinely available in line with local or regional guidance	26/02/2018
	<a href="http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/baricitinib_Olumiant_FINAL_August_2017_Amended_03.09.16_for_website.pdf</a>		
<b>Beclomethasone, formoterol, glycopyrronium</b> metered dose inhaler <b>Trimbow®</b> 1274/17	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist.	Routinely available in line with national guidance	23/10/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/beclometasone_Trimbow_Abbreviated_FINAL_Sept_2107_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/beclometasone_Trimbow_Abbreviated_FINAL_Sept_2107_for_website.pdf</a>		
<b>Belimumab</b> infusion <b>Benlysta®</b> 775/12	Add-on therapy in adult patients with active, autoantibody-positive systemic lupus erythematosus (SLE) with a high degree of disease activity (e.g. positive anti-dsDNA and low complement) despite standard therapy.	Routinely available in line with national guidance	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/belimumab_Benlysta_Resub_FINAL_April_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/belimumab_Benlysta_Resub_FINAL_April_2017_for_website.pdf</a>		
<b>Benralizumab</b> injection <b>Fasenra®</b> SMC2155	As an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting $\beta$ -agonists.	Routinely available in line with national guidance	10/06/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Bevacizumab</b> infusion <b>Avastin®</b> 1190/16	In combination with erlotinib for first-line treatment of adult patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer with Epidermal Growth Factor Receptor (EGFR) activating mutations.	Not routinely available as not recommended for use in NHSScotland	10/10/2016
	<a href="http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2016_for_website.pdf</a>		
<b>Bevacizumab</b> infusion <b>Avastin®</b> 1135/16	In combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in patients who cannot receive platinum therapy, for the treatment of adult patients with persistent, recurrent, or metastatic carcinoma of the cervix.	Routinely available in line with local or regional guidance	13/06/2016
<b>Bevacizumab</b> infusion <b>Avastin®</b> 1275/17	In combination with carboplatin and paclitaxel for the treatment of adult patients with first recurrence of platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.	Not routinely available as not recommended for use in NHSScotland	23/10/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/bevacizumab_Avastin_Non_Sub_FINAL_August_2017_for_website.pdf</a>		
<b>Bezlotoxumab</b> infusion <b>Zinplava®</b> 1293/17	Prevention of recurrence of Clostridium difficile infection (CDI) in adults at high risk for recurrence of CDI.	Not routinely available as not recommended for use in NHSScotland	11/12/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Bictegravir, Emtricitabine, Tenofovir</b> tablets Biktarvy® SMC2093	Treatment of adults infected with human immunodeficiency virus 1 (HIV-1) without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir.	Routinely available in line with national guidance	08/10/2018
<b>Biologic agents (see below)</b>  MTA 375	Rheumatoid arthritis (medicines are adalimumab, etanercept, infliximab, certolizumab, golimumab, abatacept, tocilizumab)	Routinely available in line with national guidance	18/04/2016
<b>Biologic agents (See below)</b>  MTA 383	<a href="https://www.nice.org.uk/guidance/ta375">https://www.nice.org.uk/guidance/ta375</a> Ankylosing spondylitis and axial spondyloarthritis (non-radiographic) : medicines are adalimumab, certolizumab, etanercept, infliximab, golimumab	Routinely available in line with national guidance	18/04/2016
<b>Blinatumomab</b> infusion Blincyto® 1145/16	<a href="https://www.nice.org.uk/guidance/ta383">https://www.nice.org.uk/guidance/ta383</a> The treatment of adults with Philadelphia chromosome negative relapsed or refractory B-precursor acute lymphoblastic leukaemia (ALL).	Routinely available in line with local or regional guidance	13/06/2016



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Blinatumomab</b> infusion <b>Blinicyto®</b> SMC2148	As monotherapy for the treatment of paediatric patients aged 1 year or older with Philadelphia chromosome negative CD19 positive B-cell precursor acute lymphoblastic leukaemia which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic hematopoietic stem cell transplantation.	Routinely available in line with national guidance	29/04/2019
<b>Blinatumomab</b> infusion <b>Blinicyto®</b> SMC2234	Monotherapy for the treatment of adults with Philadelphia chromosome negative, CD19 positive, B-precursor acute lymphoblastic leukaemia (ALL) in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1%.	Routinely available in line with local or regional guidance	06/07/2020
<b>Bosutinib</b> tablets <b>Bosulif®</b> 2109	Treatment of adult patients with newly diagnosed chronic phase Philadelphia chromosome-positive chronic myelogenous leukaemia.	Not routinely available as not recommended for use in NHSScotland	13/08/2018
<b>Botulinum toxin A</b> injection <b>Botox®</b> 692/11	Prophylaxis of headaches in adults with chronic migraine (headaches on at least 15 days per month of which at least 8 days are with migraine).	Routinely available in line with local or regional guidance	20/02/2017
	<a href="https://www.scottishmedicines.org.uk/medicines-advice/bosutinib-bosulif-non-submission-smc2109/">https://www.scottishmedicines.org.uk/medicines-advice/bosutinib-bosulif-non-submission-smc2109/</a>		
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/692_11_botulinum_toxin_type_a_BOTOX/botulinum_toxin_A_Botox_2nd_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/692_11_botulinum_toxin_type_a_BOTOX/botulinum_toxin_A_Botox_2nd_Resub</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Brentuximab</b> infusion Adcetris® SMC2098	Treatment of adult patients with CD30+ cutaneous T-cell lymphoma after at least one prior systemic therapy.  <a href="https://www.scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-non-submission-smc2098/">https://www.scottishmedicines.org.uk/medicines-advice/brentuximab-vedotin-adcetris-non-submission-smc2098/</a>	Not routinely available as not recommended for use in NHSScotland	13/08/2018
<b>Brentuximab vedotin</b> infusion Adcetris® SMC2202	Treatment of adult patients with previously untreated CD30+ Stage IV Hodgkin lymphoma in combination with doxorubicin, vinblastine and dacarbazine.	Not routinely available as not recommended for use in NHSScotland	10/06/2019
<b>Brentuximab Vedotin</b> infusion Adcetris® SMC2229	Treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.	Routinely available in line with local or regional guidance	24/02/2020
<b>Brentuximab vedotin</b> infusion Adcetris® SMC2025	Treatment of adult patients with CD30+ Hodgkin lymphoma at increased risk of relapse or progression following autologous stem cell transplant.	Not routinely available as not recommended for use in NHSScotland	11/06/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Brigatinib</b> tablets Alunbrig® SMC2147	as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK) positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib	Routinely available in line with local or regional guidance	10/06/2019
<b>Brivaracetam</b> tablets, infusion, injection Briviact® SMC2113	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in children from 4 years to ≤15 years of age with epilepsy.	Routinely available in line with national guidance	25/02/2019
<b>Brivaracetam</b> tablets, oral solution, injection/infusion Briviact® 1160/16	Adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent patients from 16 years of age with epilepsy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1160_16_brivaracetam_Briviact/brivaracetam_Briviact">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1160_16_brivaracetam_Briviact/brivaracetam_Briviact</a>	Routinely available in line with national guidance	22/08/2016
<b>Brodalumab</b> pre-filled syringe Kyntheum® 1283/17	for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.	Not routinely available as not recommended for use in NHSScotland	11/12/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Brodalumab</b> injection, pre-filled syringe  Kyntheum®  1283/17	Treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.	Routinely available in line with local or regional guidance	09/12/2019
		31/12/2018	
<b>Budesonide</b> prolonged-release tablets  Cortiment®  1093/15	In adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient.	Routinely available in line with national guidance	10/10/2016
	<a href="http://www.scottishmedicines.org.uk/files/advice/budesonide_Cortiment_Resub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/budesonide_Cortiment_Resub_FINAL_Sept_2016_for_website.pdf</a>		
<b>Budesonide</b> Rectal Foam  Budenofalk®  409/07	Treatment of active ulcerative colitis that is limited to the rectum and the sigmoid colon.	Routinely available in line with national guidance	23/10/2017
	<a href="http://www.scottishmedicines.org.uk/files/409_07_budesonide_Budenofalk_Abb_Sept07.pdf">http://www.scottishmedicines.org.uk/files/409_07_budesonide_Budenofalk_Abb_Sept07.pdf</a>		
<b>Budesonide/formoterol</b> inhalation powder  Symbicort® SMART®  1244/17	The regular treatment of asthma where use of a combination (inhaled corticosteroid and a long-acting $\beta$ 2 adrenoceptor agonist is appropriate: patients not adequately controlled with inhaled corticosteroids and as needed short-acting $\beta$ 2 adrenoceptor agonists, or patients already adequately controlled on both inhaled corticosteroids and long-acting $\beta$ 2 adrenoceptor agonists	Routinely available in line with national guidance	23/10/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/budesonide-formoterol_Symbicort_SMART_Abb_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/budesonide-formoterol_Symbicort_SMART_Abb_FINAL_May_2017_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Budesonide/Formoterol</b> inhaler Symbicort® 1198/16	Treatment of patients with chronic obstructive pulmonary disease (COPD) with forced expiratory volume in 1 second (FEV1) 50% to 70% predicted normal (post bronchodilator) and an exacerbation history despite regular bronchodilator therapy.  <a href="http://www.scottishmedicines.org.uk/files/advice/budesonide_formoterol_Symbicort_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/budesonide_formoterol_Symbicort_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<b>Buprenorphine</b> oral lyophilisate Espranor® 1245/17	Substitution treatment for opioid drug dependence, within a framework of medical, social and psychological treatment. Treatment with buprenorphine oral lyophilisate is intended for use in adults and adolescents aged 15 years or over who have agreed to be treated for addiction.  <a href="http://www.scottishmedicines.org.uk/files/advice/buprenorphine_oral_lyophilisate_Espranor_Abb_FINAL_May_2017_amended_050617_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/buprenorphine_oral_lyophilisate_Espranor_Abb_FINAL_May_2017_amended_050617_for_website.pdf</a>	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	19/06/2017
<b>Buprenorphine</b> transdermal patch Butec® 1213/17	In adults, for the treatment of chronic non-malignant pain of moderate intensity when an opioid is necessary for obtaining adequate analgesia.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1213_17_buprenorphine_transdermal_patch_Butec/buprenorphine_transdermal_patch.pdf">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1213_17_buprenorphine_transdermal_patch_Butec/buprenorphine_transdermal_patch.pdf</a>	Routinely available in line with local or regional guidance	20/02/2017
<b>Buprenorphine</b> prolonged-release injection Buvidal® SMC2169	Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 years or over.	Routinely available in line with national guidance	12/08/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Buprenorphine with Naloxone</b> sublingual tablets Suboxone®	Substitution treatment for opioid drug dependence	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	11/12/2017
<b>Cabazitaxel</b> infusion Jevtana® 735/11	In combination with prednisone or prednisolone, is indicated for the treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Cabazitaxel</b> infusion Jevtana® 735/11	In combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.	Routinely available in line with local or regional guidance	12/12/2016
<b>Cabozantinib</b> tablets Cabometyx® 1234/17	For the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy.	Routinely available in line with local or regional guidance	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/735_11_cabazitaxel_Jevtana/cabazitaxel_Jevtana_2nd_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/735_11_cabazitaxel_Jevtana/cabazitaxel_Jevtana_2nd_Resub</a> <a href="http://www.scottishmedicines.org.uk/files/advice/cabozantinib_Cabometyx_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/cabozantinib_Cabometyx_FINAL_May_2017_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Cabozantinib</b> tablets  Cabometyx®  SMC2136	Advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk.	Not routinely available as not recommended for use in NHSScotland	25/02/2019
<b>Cabozantinib</b> tablets  Cabometyx®  SMC2160	Monotherapy for the treatment of hepatocellular carcinoma in adults who have previously been treated with sorafenib.	Not routinely available as not recommended for use in NHSScotland	25/02/2019
<b>Cabozantinib</b> tablets  Cabometyx®  SMC2095	Advanced renal cell carcinoma (RCC) in treatment-naïve adults with intermediate or poor risk.	Not routinely available as not recommended for use in NHSScotland	08/10/2018
<b>Calcipotriol, betamethasone</b> cutaneous foam  Enstilar®  1182/16	Topical treatment of psoriasis vulgaris in adults	Routinely available in line with national guidance	10/10/2016
<a href="http://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone_Enstilar_Abb_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/calcipotriol_betamethasone_Enstilar_Abb_FINAL_August_2016_for_website.pdf</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Camellia sinensis (green tea) leaf</b> extract Catephen® 1133/16	Cutaneous treatment of external genital and perianal warts (condylomata acuminata) in immunocompetent patients from the age of 18 years.  <a href="http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Routinely available in line with national guidance	18/04/2016
<b>Canagliflozin, dapagliflozin, empagliflozin</b> oral  MTA 390	as monotherapy for type 2 diabetes in adults for whom use of metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control  <a href="https://www.nice.org.uk/guidance/ta390">https://www.nice.org.uk/guidance/ta390</a>	Routinely available in line with national guidance	22/08/2016
<b>Canakinumab</b> injection Ilaris® 1268/17	Treatment of the following autoinflammatory periodic fever syndromes in adults, adolescents and children aged 2 years and older: - tumour necrosis factor receptor associated periodic syndrome - hyperimmunoglobulin D syndrome / mevalonate kinase deficiency - Familial Mediterranean Fever  <a href="http://www.scottishmedicines.org.uk/files/advice/canankinumab_Ilaris_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/canankinumab_Ilaris_Non_Sub_FINAL_July_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Canakinumab</b> injection <b>Ilaris®</b> 1210/16	Treatment of active Still's disease including Adult-Onset Still's Disease who have responded inadequately to previous therapy with non-steroidal anti-inflammatory drugs (NSAIDs) and systemic corticosteroids. Ilaris can be given as monotherapy or in combination with methotrexate.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_Ilaris/canakinumab_Ilaris_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1210_16_canakinumab_Ilaris/canakinumab_Ilaris_non_submission</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Capsaicin</b> cutaneous patch <b>Qutenza®</b> 1140/16	Treatment of peripheral neuropathic pain in diabetic adults either alone or in combination with other medicinal products for pain.	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Carbetocin</b> injection <b>Pabal®</b> 309/06	For the prevention of uterine atony following delivery of the infant by Caesarean section under epidural or spinal anaesthesia	Not routinely available as not recommended for use in NHSScotland	26/02/2018
<b>Carfilzomib</b> infusion <b>Kyprolis®</b> 1171/16	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.  <a href="http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_August_2016_revised_080916_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_August_2016_revised_080916_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Carfilzomib</b> infusion Kyprolis® 1171/16	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as not recommended for use in NHSScotland	20/02/2017
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1171_16_carfilzomib_Kyprolis/carfilzomib_Kyprolis_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1171_16_carfilzomib_Kyprolis/carfilzomib_Kyprolis_Resub</a>		
<b>Carfilzomib</b> infusion Kyprolis® 1242/17	In combination with dexamethasone alone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Routinely available in line with local or regional guidance	28/08/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/carfilzomib_Kyprolis_FINAL_July_2017_for_website.pdf</a>		
<b>Cariprazine</b> capsules Reagila® SMC2137	Treatment of schizophrenia in adult patients.	Routinely available in line with national guidance	10/06/2019
<b>Ceftaroline fosamil</b> infusion Zinforo® 1306/18	treatment of: - complicated skin and soft tissue infections in children from the age of 2 months - community-acquired pneumonia in children from the age of 2 months	Not routinely available as not recommended for use in NHSScotland	26/02/2018
	<a href="http://www.scottishmedicines.org.uk/files/advice/ceftaroline_fosamil_Zinforo_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ceftaroline_fosamil_Zinforo_Non_Sub_FINAL_Dec_2017_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ceftazadime with Avibactam</b> Infusion <b>Zavicefta</b> 1307/18	Treatment of the following infections in adults: 1) complicated intra-abdominal Infection (cIAI); 2) complicated urinary tract infection (cUTI), including pyelonephritis; 3) hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP); 4) infections due to aerobic Gram-negative organisms in adult patients with limited treatment options  <a href="http://www.scottishmedicines.org.uk/files/advice/ceftazidime_avibactam_Zavicefta_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ceftazidime_avibactam_Zavicefta_Non_Sub_FINAL_Dec_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	26/02/2018
<b>Ceftolozane with Tazobactam</b> infusion <b>Zerbaxa®</b> 1146/16	Treatment of the following infections in adults: - Complicated intra-abdominal infections - Acute pyelonephritis - Complicated urinary tract infections	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Ceftolozane/Tazobactam</b> infusion <b>Zerbaxa®</b> SMC2256	In adults for the treatment of hospital acquired pneumonia, including ventilator-associated pneumonia.	Not routinely available as not recommended for use in NHSScotland	09/12/2019
<b>Cefuroxime</b> intracameral injection <b>Aprokam®</b> 932/13	Antibiotic prophylaxis of postoperative endophthalmitis after cataract surgery.	Routinely available in line with national guidance	12/12/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/932_13_cefuroxime_sodium_Aprokam/cefuroxime_Aprokam_Abbreviated">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/932_13_cefuroxime_sodium_Aprokam/cefuroxime_Aprokam_Abbreviated</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Cemiplimab</b> infusion Libtayo® SMC2216	As monotherapy for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who are not candidates for curative surgery or curative radiation.	Routinely available in line with local or regional guidance	24/02/2020
<b>Cenergermin</b> eye drops Oxervate® SMC2124	Treatment of moderate (persistent epithelial defect) or severe (corneal ulcer) neurotrophic keratitis in adults.	Not routinely available as not recommended for use in NHSScotland	08/10/2018
<b>Ceritinib</b> hard capsules Zykadia ® 1333/18	As monotherapy for the first-line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer.	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<b>Certolizumab and Secukinumab</b>  TA445	Active psoriatic arthritis after inadequate response to DMARDs  <a href="https://www.nice.org.uk/guidance/ta445">https://www.nice.org.uk/guidance/ta445</a>	Routinely available in line with national guidance	28/08/2017
	<a href="https://www.scottishmedicines.org.uk/medicines-advice/ceritinib-zykadia-nonsub-133318/">https://www.scottishmedicines.org.uk/medicines-advice/ceritinib-zykadia-nonsub-133318/</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Certolizumab pegol</b> injection Cimzia® 1155/16	Treatment of severe, active and progressive RA in adults not previously treated with MTX or other DMARDs.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Certolizumab Pegol</b> injection Cimzia® SMC2132	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy	Routinely available in line with national guidance  01/11/2019	09/12/2019
<b>Chenodeoxycholic acid</b> capsules Chenodeoxycholic acid Leadiant® SMC2190	Treatment of inborn errors of primary bile acid synthesis due to sterol 27 hydroxylase deficiency (presenting as cerebrotendinous xanthomatosis) in infants, children and adolescents aged 1 month to 18 years and adults.	Not routinely available as not recommended for use in NHSScotland	10/06/2019
<b>Ciclosporin</b> eye drops emulsion Verkazia® SMC2111	Treatment of severe vernal keratoconjunctivitis (VKC) in children from 4 years of age and adolescents.	Routinely available in line with national guidance	25/02/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Cinacalcet</b> capsules Mimpara® SMC2275	Secondary hyperparathyroidism (HPT): - Treatment of secondary HPT in adult patients with end-stage renal disease (ESRD) on maintenance dialysis therapy. - Treatment of secondary HPT in children aged 3 years and older with ESRD on maintenance dialysis therapy in whom secondary HPT is not adequately controlled with standard of care therapy Parathyroid carcinoma and primary HPT in adults - Reduction of hypercalcaemia in adult patients with: - parathyroid carcinoma. - primary HPT for whom parathyroidectomy would be indicated on the basis of serum calcium levels, but in whom parathyroidectomy is not clinically appropriate or is contraindicated	Not routinely available as not recommended for use in NHSScotland	06/07/2020
<b>Ciprofloxacin</b> ear drops Cetraxal® 1320/18	Treatment of acute otitis externa in adults and children older than 1 year with an intact tympanic membrane, caused by ciprofloxacin susceptible microorganisms.  <a href="https://www.scottishmedicines.org.uk/medicines-advice/ciprofloxacin-hydrochloride-cetraxal-abbreviatedsubmission-132018/">https://www.scottishmedicines.org.uk/medicines-advice/ciprofloxacin-hydrochloride-cetraxal-abbreviatedsubmission-132018/</a>	Routinely available in line with national guidance	23/04/2018
<b>Ciprofloxacin with Dexamethasone</b> ear drops Cilodex® 1256/17	Treatment of the following infections in adults and children: - Acute otitis media in patients with tympanostomy tubes (AOMT) - Acute otitis externa  <a href="http://www.scottishmedicines.org.uk/files/advice/ciprofloxacin-dexamethasone_Cilodex_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ciprofloxacin-dexamethasone_Cilodex_Abbreviated_FINAL_June_2017_for_website.pdf</a>	Routinely available in line with national guidance	28/08/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Cladribine</b> tablet Mavenclad® 1300/18  <a href="http://www.scottishmedicines.org.uk/files/advice/cladribine_Mavenclad_FINAL_Jan_2018_Amended_07.02.18_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/cladribine_Mavenclad_FINAL_Jan_2018_Amended_07.02.18_for_website.pdf</a>	Treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features.	Routinely available in line with local or regional guidance	26/02/2018
<b>Clostridium botulinum neurotoxin type A</b> injection Xeomin® SMC2212	Symptomatic treatment of chronic sialorrhoea due to neurological disorders in adults.	Routinely available in line with national guidance	09/12/2019
<b>Clostridium botulinum type A toxin</b> injection I Dysport® 1321/18  <a href="https://www.scottishmedicines.org.uk/medicines-advice/clostridium-botulinum-type-a-toxin-haemagglutinin-complex-300-and-500-units-dysport-no">https://www.scottishmedicines.org.uk/medicines-advice/clostridium-botulinum-type-a-toxin-haemagglutinin-complex-300-and-500-units-dysport-no</a>	Symptomatic treatment of focal spasticity of lower limbs in adults affecting the ankle joint due to stroke or traumatic brain injury.	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<b>Cobimetinib</b> tablets Cotellic® 1191/16  <a href="http://www.scottishmedicines.org.uk/files/advice/cobimetinib_Cotellic_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/cobimetinib_Cotellic_Non_Sub_FINAL_August_2016_for_website.pdf</a>	In combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Not routinely available as not recommended for use in NHSScotland	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Co-careldopa</b> intestinal gel <b>Duodopa®</b> 316/06	Treatment of advanced levodopa-responsive Parkinson's disease with severe motor fluctuations and hyper-/dyskinesia when available combinations of Parkinson medicinal products have not given satisfactory results.	Routinely available in line with national guidance	13/06/2016
<b>Collagenase clostridium histolyticum</b> injection <b>Xiapex®</b> MTA 459	Dupuytren's contracture	Routinely available in line with national guidance	23/10/2017
<b>Conestat Alfa</b> injection <b>Ruconest®</b> 745/11	<p> <a href="https://www.nice.org.uk/Guidance/TA459">https://www.nice.org.uk/Guidance/TA459</a>            For treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency         </p>	Routinely available in line with national guidance	13/08/2018
<b>Crizotinib</b> hard capsules <b>Xalkori®</b> 1152/16	<p> <a href="https://www.scottishmedicines.org.uk/media/3647/conestat-alfa-ruconest-final-20180808-for-website.pdf">https://www.scottishmedicines.org.uk/media/3647/conestat-alfa-ruconest-final-20180808-for-website.pdf</a>            First-line treatment of adults with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).         </p>	Routinely available in line with local or regional guidance	22/08/2016
	<p> <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1152_16_crizotinib_Xalkori/crizotinib_Xalkori">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1152_16_crizotinib_Xalkori/crizotinib_Xalkori</a> </p>		



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Crizotinib</b> capsules Xalkori® 1329/18	Treatment of adults with ROS1-positive advanced non-small cell lung cancer (NSCLC).	Routinely available in line with local or regional guidance	11/06/2018
<b>Cyanocobalamin</b> oral tablets	Vitamin B12 deficiency (Short-term diagnostic use - refer to Formulary for full details)	Routinely available in line with local or regional guidance	11/12/2017
<b>Dabrafenib</b> Tafinlar® capsules SMC2131	In combination with trametinib for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.	Routinely available in line with local or regional guidance	25/02/2019
<b>Daclizumab</b> pre-filled syringe or pen Zinbryta® 1216/17	In adult patients for the treatment of relapsing forms of multiple sclerosis.	Routinely available in line with national guidance	24/04/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Dacomitinib</b> tablets Vizimpro® SMC2184	Monotherapy, for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR)-activating mutations.	Routinely available in line with local or regional guidance	07/10/2019
<b>Dalbavancin</b> infusion Xydalba® 1105/15	Treatment of acute bacterial skin and skin structure infections (ABSSSI) in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1105_15_dalbavancin_Xydalba/dalbavancin_Xydalba">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1105_15_dalbavancin_Xydalba/dalbavancin_Xydalba</a>	Routinely available in line with local or regional guidance	20/02/2017
<b>Dapagliflozin</b> tablets Forxiga® SMC2185	In adults for the treatment of insufficiently controlled type 1 diabetes mellitus as an adjunct to insulin in patients with BMI $\geq 27\text{kg/m}^2$ , when insulin alone does not provide adequate glycaemic control despite optimal insulin therapy.	Routinely available in line with national guidance	07/10/2019
<b>Daptomycin</b> injection, infusion Cubicin® 1309/18	Treatment of paediatric (1 to 17 years of age) patients with Staphylococcus aureus bacteraemia associated with complicated skin and soft-tissue infections.  <a href="http://www.scottishmedicines.org.uk/files/advice/daptomicin_Cubicin_Non_Sub_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/daptomicin_Cubicin_Non_Sub_FINAL_Jan_2018_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Daptomycin</b> injection or infusion  Cubicin®  1141/16	Treatment of paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections.	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Daratumumab</b> infusion  Darzalex®  SMC2269	In combination with lenalidomide and dexamethasone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as not recommended for use in NHSScotland	24/02/2020
<b>Daratumumab</b> infusion  Darzalex®  1205/17	Monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1205_17_daratumumab_Darzalex/daratumumab_Darzalex">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1205_17_daratumumab_Darzalex/daratumumab_Darzalex</a>	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Daratumumab</b> infusion  Darzalex®  SMC2180	In combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Routinely available in line with local or regional guidance	12/08/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Daratumumab</b> infusion <b>Darzalex®</b> 1205/17	As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, whose prior therapy included a proteasome inhibitor and an immunomodulatory agent and who have demonstrated disease progression on the last therapy.  <a href="http://www.scottishmedicines.org.uk/files/advice/daratumumab_Darzalex_Resubmission_FINAL_Sept_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/daratumumab_Darzalex_Resubmission_FINAL_Sept_2017_for_website.pdf</a>	Routinely available in line with local or regional guidance	23/10/2017
<b>Daratumumab</b> infusion <b>Darzalex®</b> SMC2191	In combination with bortezomib, melphalan and prednisone for the treatment of adult patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.	Not routinely available as not recommended for use in NHSScotland	10/06/2019
<b>Darunavir, Cobicistat, Emtricitabine, Tenofovir</b> tablets <b>Symtuza®</b> 1290/18	the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).  <a href="http://www.scottishmedicines.org.uk/files/advice/darunavir_Symtuza_Abbreviated_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/darunavir_Symtuza_Abbreviated_FINAL_Dec_2017_for_website.pdf</a>	Routinely available in line with national guidance	26/02/2018
<b>Darvadstrocel</b> injection <b>Alofisel®</b> SMC2115	treatment of complex perianal fistulas in adult patients with non-active / mildly active luminal Crohn's disease, when fistulas have shown an inadequate response to at least one conventional or biologic therapy.	Not routinely available as not recommended for use in NHSScotland	12/08/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Dasatinib</b> tablets Sprycel® 370/07	The treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate  <a href="http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_Resub_FINAL_August_2016_Amended_06.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_Resub_FINAL_August_2016_Amended_06.09.16_for_website.pdf</a>	Routinely available in line with local or regional guidance	10/10/2016
<b>Dasatinib</b> tablets Sprycel® SMC2142	The treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia in chronic phase (Ph+ CML-CP) or Ph+ CML-CP resistant or intolerant to prior therapy including imatinib.	Routinely available in line with national guidance	29/04/2019
<b>Dasatinib</b> tablets Sprycel® SMC2192	Treatment of paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia in combination with chemotherapy.	Not routinely available as not recommended for use in NHSScotland	10/06/2019
<b>Dasatinib</b> tablets Sprycel® 1170/16	The treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase  <a href="http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dasatinib_Sprycel_FINAL_August_2016_for_website.pdf</a>	Routinely available in line with local or regional guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Deferasirox</b> tablets Exjade® 1246/17	Treatment of chronic iron overload due to frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older and treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate in specific patient groups as outlined in full in the SMC advice.  <a href="http://www.scottishmedicines.org.uk/files/advice/deferasiox_Exjade_Abbreviated_FINAL_May_2017_Amended_050617_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/deferasiox_Exjade_Abbreviated_FINAL_May_2017_Amended_050617_for_website.pdf</a>	Routinely available in line with national guidance	19/06/2017
<b>Deferasirox</b> dispersible tablets Exjade® 347/07	Treatment of chronic iron overload due to blood transfusions when deferoxamine therapy is contraindicated or inadequate, in adult and paediatric patients aged 2 years and older with rare acquired or inherited anaemias.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/347_07_deferasirox_Exjade/deferasiox_Exjade_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/347_07_deferasirox_Exjade/deferasiox_Exjade_Resub</a>	Routinely available in line with local or regional guidance	20/02/2017
<b>Denosumab</b> injection Xgeva® 2110	Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with haematological malignancies involving bone.  <a href="https://www.scottishmedicines.org.uk/medicines-advice/denosumab-xgeva-non-submission-smc2110/">https://www.scottishmedicines.org.uk/medicines-advice/denosumab-xgeva-non-submission-smc2110/</a>	Not routinely available as not recommended for use in NHSScotland	13/08/2018
<b>Denosumab</b> injection in pre-filled syringe Prolia® SMC2017	Treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture.	Not routinely available as not recommended for use in NHSScotland	08/10/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Dequalinium chloride</b> vaginal tablets  Floumizin®  1194/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Fluomizin/dequalinium_Fluomizin">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1194_16_dequalinium_Fluomizin/dequalinium_Fluomizin</a>	Treatment of bacterial vaginosis.	Routinely available in line with national guidance	12/12/2016
<b>Desmopressin</b> oral lyophilisate  Noqdirna®  1218/17  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1218_17_desmopressin_Noqdirna/desmopressin_Noqdirna">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1218_17_desmopressin_Noqdirna/desmopressin_Noqdirna</a>	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Desmopressin</b> oral lyophilisate  Noqdirna®  1218/17  <a href="http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf</a>	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  19/02/2018	28/08/2017
<b>Desmopressin</b> oral lyophilisate  Noqdirna®  1218/17  <a href="http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/desmopressin_Noqdirna_Resubmission_FINAL_July_2017_for_website.pdf</a>	Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults.	Routinely available in line with local or regional guidance	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Dexamethasone</b> tablets Neofordex ® 1322/18  <a href="https://www.scottishmedicines.org.uk/medicines-advice/dexamethasone-40mg-tablets-neofordex-non-submission-132218/">https://www.scottishmedicines.org.uk/medicines-advice/dexamethasone-40mg-tablets-neofordex-non-submission-132218/</a>	In adults for the treatment of symptomatic multiple myeloma in combination with other medicinal products.	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<b>Dexmedetomidine</b> infusion Dexdor® SMC2161	Sedation of non-intubated adult patients prior to and/or during diagnostic or surgical procedures requiring sedation, i.e. procedural/awake sedation.	Not routinely available as not recommended for use in NHSScotland	25/02/2019
<b>Diamorphine hydrochloride</b> nasal spray Ayendi® 1172/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1172_16_diamorphine_hydrochloride_Ayendi/diamorphine_hydrochloride_Ayendi">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1172_16_diamorphine_hydrochloride_Ayendi/diamorphine_hydrochloride_Ayendi</a>	Treatment of acute severe nociceptive pain in children and adolescents in a hospital setting. Diamorphine hydrochloride nasal spray (Ayendi®) should be administered in the emergency setting by practitioners experienced in the administration of opioids in children and with appropriate monitoring.	Routinely available in line with national guidance	22/08/2016
<b>Dimethyl fumarate</b> tablets Skilarence® 1313/18  <a href="https://www.scottishmedicines.org.uk/medicines-advice/dimethyl-fumarate-skilarence-fullsubmission/">https://www.scottishmedicines.org.uk/medicines-advice/dimethyl-fumarate-skilarence-fullsubmission/</a>	Treatment of moderate to severe plaque psoriasis in adults in need of systemic medicinal therapy.	Routinely available in line with national guidance	23/04/2018



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Dinutuximab beta</b> infusion <b>Qarziba</b> SMC2105	Treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease	Routinely available in line with national guidance	25/02/2019
<b>Dolutegravir</b> tablets <b>Tivicay®</b> 1253/17	in combination with other anti-retroviral medicinal products for the treatment of Human Immunodeficiency Virus (HIV) infected children aged >6 to 12 years of age.  <a href="http://www.scottishmedicines.org.uk/files/advice/dolutegravir_Tivicay_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/dolutegravir_Tivicay_Abbreviated_FINAL_June_2017_for_website.pdf</a>	Routinely available in line with national guidance	23/10/2017
<b>Dolutegravir + lamivudine</b> tablet <b>Dovato®</b> SMC2205	treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine	Routinely available in line with national guidance	07/10/2019
<b>Dolutegravir with Rilpivirine</b> tablets <b>Juluca®</b> SMC2091	The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically-suppressed (HIV-1 RNA <50 copies/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase inhibitor	Routinely available in line with national guidance	08/10/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Doravirine</b> tablets <b>Pifeltro®</b> SMC2162</p>	<p>In combination with other antiretroviral medicinal products, for the treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>25/02/2019</p>
<p><b>Doravirine, lamivudine, tenofovir</b> tablet <b>Delstrigo®</b> SMC2163</p>	<p>Treatment of adults infected with human immunodeficiency virus 1 without past or present evidence of resistance to the non-nucleoside reverse transcriptase inhibitor class, lamivudine, or tenofovir.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>25/02/2019</p>
<p><b>Doxylamine &amp; Pyridoxine</b> tablets <b>Xonvea®</b> SMC2140</p>	<p>Treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>10/06/2019</p>
<p><b>Dulaglutide</b> injection <b>Trulicity®</b> 1110/15</p>	<p>In adults with type 2 diabetes mellitus to improve glycaemic control as add-on therapy in combination with other glucose-lowering medicinal products including insulin, when these, together with diet and exercise, do not provide adequate glycaemic control.</p>	<p>Routinely available in line with national guidance</p>	<p>22/02/2016</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Dupilumab</b> subcutaneous injection</p> <p>Dupixent®</p> <p>SMC2011</p>	<p>The treatment of moderate-to-severe atopic dermatitis in adult patients who are candidates for systemic therapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>25/02/2019</p>
<p><b>Durvalumab</b> infusion</p> <p>Imfinzi®</p> <p>SMC2156</p>	<p>As monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express PD-L1 [programmed cell death ligand 1] on ≥1% of tumour cells and whose disease has not progressed following platinum-based chemoradiation therapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>10/06/2019</p>
<p><b>Eculizumab</b> infusion</p> <p>Soliris®</p> <p>767/12</p>	<p>In adults and children for the treatment of patients with atypical haemolytic uraemic syndrome (aHUS)</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>22/02/2016</p>
<p><b>Eculizumab</b> infusion</p> <p>Soliris®</p> <p>SMC2236</p>	<p>Treatment of adults with refractory generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>07/10/2019</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Eculizumab</b> infusion <b>Soliris®</b> 1130/16	In adults and children, for the treatment of patients with paroxysmal nocturnal haemoglobinuria (PNH). Evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Elbasvir and grazoprevir</b> tablets <b>Zepatier®</b> 1203/17	Treatment of chronic hepatitis C (CHC) in adults. (The efficacy of elbasvir-grazoprevir has not been demonstrated in genotypes 2, 3, 5 and 6. Elbasvir-grazoprevir is not recommended in patients infected with these genotypes).  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1203_17_elbasvir-grazoprevir_Zepatier/elbasvir-grazoprevir_Zepatier">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1203_17_elbasvir-grazoprevir_Zepatier/elbasvir-grazoprevir_Zepatier</a>	Routinely available in line with national guidance	20/02/2017
<b>Eliglustat</b> capsules <b>Cerdelga®</b> 1277/17	Long-term treatment of adult patients with Gaucher disease type 1 (GD1) who are CYP2D6 poor metabolisers, intermediate metabolisers or extensive metabolisers	Routinely available in line with national guidance	11/12/2017
<b>Elotuzumab</b> infusion <b>Empliciti®</b> 1183/16	Treatment of multiple myeloma in combination with lenalidomide and dexamethasone in adult patients who have received at least one prior therapy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1183_16_elotuzumab_Empliciti/elotuzumab_Empliciti">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1183_16_elotuzumab_Empliciti/elotuzumab_Empliciti</a>	Not routinely available as not recommended for use in NHSScotland	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Eltrombopag</b> tablets Revolade® 1206/17	Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients aged 1 year to 17 years who are refractory to other treatments (e.g. corticosteroids, immunoglobulins).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  24/04/2017	20/02/2017
<b>Eltrombopag olamine</b> tablets Revolade® 1164/16	Treatment in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1164_16_eltrombopag_olamine_Ravolade/eltrombopag_olamine_Revolade_Non_submi">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1164_16_eltrombopag_olamine_Ravolade/eltrombopag_olamine_Revolade_Non_submi</a>			
<b>Eluxadoline</b> tablets Truberzi® 1292/18	in adults for the treatment of irritable bowel syndrome with diarrhoea (IBS-D).	Not routinely available as not recommended for use in NHSScotland	26/02/2018
<a href="http://www.scottishmedicines.org.uk/files/advice/eluxadoline_Truberzi_FINAL_Dec_2017_Amended_14.12.17_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/eluxadoline_Truberzi_FINAL_Dec_2017_Amended_14.12.17_for_website.pdf</a>			
<b>Elvitegra/cobicistat/emtricitab/tenofo/ralafenam</b> tablets Genvoya ® 1323/18	Treatment of human immunodeficiency virus-1 (HIV-1) infection without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir in children aged from 6 years and with body weight at least 25 kg for whom alternative regimens are unsuitable due to toxicities.	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<a href="https://www.scottishmedicines.org.uk/medicines-advice/elvitegravir-150mg-cobicistat-150-mg-emtricitabine-200-mg-tenofovir-ralafenamide-10-mg-">https://www.scottishmedicines.org.uk/medicines-advice/elvitegravir-150mg-cobicistat-150-mg-emtricitabine-200-mg-tenofovir-ralafenamide-10-mg-</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Elvitegravir, Cobicistat, Emtricitabine, Tenofovir</b> tablets Stribild® 1310/18	Treatment of HIV-1 infection in adolescents aged 12 to <18 years weighing ≥35kg who are infected with HIV-1 without known mutations associated with resistance to any of the three antiretroviral agents in Stribild® and who have experienced toxicities which preclude the use of other regimens that do not contain tenofovir disoproxil fumarate.  <a href="http://www.scottishmedicines.org.uk/files/advice/elvit_cobic_emtric_Stribild_Non_Sub_FINAL_Jan_2018_with_website.pdf">http://www.scottishmedicines.org.uk/files/advice/elvit_cobic_emtric_Stribild_Non_Sub_FINAL_Jan_2018_with_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	26/02/2018
<b>Empagliflozin plus Linagliptin</b> tablets Glyxambi® SMC 1236/17	in adults aged 18 years and older with type 2 diabetes mellitus: - To improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Glyxambi® do not provide adequate glycaemic control - When already being treated with the free combination of empagliflozin and linagliptin	Routinely available in line with national guidance	12/08/2019
<b>Emtricitabine with Tenofovir disoproxil</b> tablets Truvada 1263/17	Treatment of HIV-1 infected adolescents aged 12 to <18 years with nucleoside reverse transcriptase inhibitor resistance or toxicities precluding the use of first line agents	Not routinely available as not recommended for use in NHSScotland	28/08/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/emtricitabine-tenofovir_disoproxil_Truvada_Non_Submission_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/emtricitabine-tenofovir_disoproxil_Truvada_Non_Submission_FINAL_June_2017_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Emtricitabine/tenofovir alafenamide</b> tablets Descovy® 1169/16	In combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus type 1.	Routinely available in line with national guidance	22/08/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1169_16_emtricitabine_tenofovir_alafenamide_Descovy/emtricitabine_tenofovir_alafena">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1169_16_emtricitabine_tenofovir_alafenamide_Descovy/emtricitabine_tenofovir_alafena</a>		
<b>Emtricitabine/tenofovir disoproxil</b> tablets Truvada® 1225/17	In combination with safer sex practices for pre-exposure prophylaxis to reduce the risk of sexually acquired HIV-1 infection in adults at high risk.	Routinely available in line with national guidance	24/04/2017
<b>Encorafenib</b> capsules Braftovi® SMC2145	In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Not routinely available as not recommended for use in NHSScotland	12/08/2019
<b>Encorafenib plus Binimetinib</b> Capsules Braftovi® SMC2238	In combination with binimetinib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.	Routinely available in line with local or regional guidance	24/02/2020

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Enzalutamide</b> soft capsules Xtandi 1066/15	Treatment of adult men with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1066_15_enzalutamide_Xtandi/Briefing_note_enzalutamide_Xtandi_IRP">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1066_15_enzalutamide_Xtandi/Briefing_note_enzalutamide_Xtandi_IRP</a>	Routinely available in line with local or regional guidance	18/04/2016
<b>Enzalutamide</b> capsules Xtandi® SMC2195	The treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (CRPC).	Not routinely available as not recommended for use in NHSScotland	07/10/2019
<b>Epoetin Alfa</b> Pre-filled Syringe Eprex® SMC2164	Treatment of symptomatic anaemia (haemoglobin concentration of $\leq 10\text{g/dL}$ ) in adults with low- or intermediate-1-risk primary myelodysplastic syndromes (MDS) who have low serum erythropoietin ( $< 200\text{ mU/mL}$ ).	Not routinely available as not recommended for use in NHSScotland	29/04/2019
<b>Erenumab</b> injection Aimovig® SMC2134	The prophylaxis of migraine in adults who have at least four migraine days per month.	Routinely available in line with local or regional guidance	29/04/2019



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Eribulin</b> injection Halaven® SMC2231	Treatment of adult patients with unresectable liposarcoma who have received prior anthracycline containing therapy (unless unsuitable) for advanced or metastatic disease.	Not routinely available as not recommended for use in NHSScotland	07/10/2019
<b>Eribulin (mesilate)</b> injection Halaven® 1065/15	Treatment of adults with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1065_15_eribulin_Halaven/Briefing_note_eribulin_Halaven_Resubmission</a>	Routinely available in line with local or regional guidance	18/04/2016
<b>Erlotinib, Gefitinib</b>  TA374	Non-small cell lung cancer post chemotherapy	Routinely available in line with national guidance	22/02/2016
<b>Ertugliflozin</b> tablet Steglatro® SMC2102	In adults aged 18 years and older with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycaemic control: -As monotherapy in patients for whom the use of metformin is considered inappropriate due to intolerance or contraindications. -In addition to other medicinal products for the treatment of diabetes.	Routinely available in line with national guidance	25/02/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Eslicarbazepine acetate</b> tablets Zebinix® SMC2090	As monotherapy in the treatment of partial-onset seizures, with or without secondary generalisation, in adults with newly diagnosed epilepsy.	Not routinely available as not recommended for use in NHSScotland	11/06/2018
<b>Eslicarbazepine acetate</b> tablet, oral suspension Zebinix® SMC2087	Adjunctive therapy in adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation.	Routinely available in line with national guidance	29/04/2019
<b>Etelcalcetide</b> injection Parsabiv® 1262/17	Treatment of secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis therapy.	Not routinely available as not recommended for use in NHSScotland	23/10/2017
<b>Everolimus</b> dispersible tablets Votubia® 1331/18	Adjunctive treatment of patients aged two years and older whose refractory partial-onset seizures, with or without secondary generalisation, are associated with tuberous sclerosis complex (TSC).	Routinely available in line with national guidance	11/06/2018

[http://www.scottishmedicines.org.uk/files/advice/etelcalcetide\\_Parsabiv\\_FINAL\\_August\\_2017\\_amended\\_030917\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/etelcalcetide_Parsabiv_FINAL_August_2017_amended_030917_for_website.pdf)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Everolimus</b> tablets Afinitor® 872/13	Treatment of hormone receptor-positive, HER2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence or progression following a non-steroidal aromatase inhibitor.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a>	Routinely available in line with local or regional guidance	18/04/2016
<b>Everolimus</b> tablets Certican® 1288/17	Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogenic renal transplant.	Not routinely available as not recommended for use in NHSScotland	11/12/2017
<b>Everolimus</b> tablets Afinitor® 1215/17	Treatment of unresectable or metastatic, well-differentiated (Grade 1 or Grade 2) non-functional neuroendocrine tumours of gastrointestinal or lung origin in adults with progressive disease.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1215_17_everolimus_Afinitor/everolimus_Afinitor_NETs">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1215_17_everolimus_Afinitor/everolimus_Afinitor_NETs</a>	Routinely available in line with local or regional guidance	20/02/2017
<b>Everolimus and Sunitinib</b>  MTA 449	Unresectable or metastatic neuroendocrine tumours in people with progressive disease  <a href="https://www.nice.org.uk/guidance/ta449">https://www.nice.org.uk/guidance/ta449</a>	Routinely available in line with local or regional guidance	28/08/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Evolocumab</b> injection Repatha® PFS 1148/16	In adults with primary hypercholesterolaemia or mixed dyslipidaemia or in adults and adolescents aged 12 years and over with homozygous familial hypercholesterolaemia (see SMC advice for full details of indication)	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Evolocumab</b> injection Repatha SMC2133	In adults with established atherosclerotic cardiovascular disease (myocardial infarction, stroke or peripheral arterial disease) to reduce cardiovascular risk by lowering LDL-C levels, as an adjunct to correction of other risk factors: - in combination with the maximum tolerated dose of a statin with or without other lipid-lowering therapies or, - alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.	Not routinely available as not recommended for use in NHSScotland	10/12/2018
<b>Evolocumab</b> injection Repatha® 1148/16	In adults with primary hypercholesterolaemia (heterozygous familial hypercholesterolaemia and non-familial) or mixed dyslipidaemia, as an adjunct to diet: [1] in combination with a statin or statin with other lipid lowering therapies in patients unable to reach low density lipoprotein-cholesterol (LDL-C) goals with the maximum tolerated dose of a statin or, [2] alone or in combination with other lipid-lowering therapies in patients who are statin-intolerant, or for whom a statin is contraindicated.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1148_16_evolocumab_Repatha/evolocumab_Repatha_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1148_16_evolocumab_Repatha/evolocumab_Repatha_Resub</a>	Routinely available in line with local or regional guidance	20/02/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Fampridine</b> prolonged-release tablets Fampyra® 789/12	For the improvement of walking in adult patients with multiple sclerosis (MS) with walking disability (EDSS [expanded disability status scale] 4 to 7).  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/789_12_fampridine_Fampyra/fampridine_Fampyra</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Fampridine</b> tablets Fampyra SMC2107	For the improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).	Not routinely available as not recommended for use in NHSScotland	10/12/2018
<b>Fampridine</b> tablet Fampyra® SMC2253	Improvement of walking in adult patients with multiple sclerosis with walking disability (EDSS [expanded disability status scale] 4-7).	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  31/12/2020	06/07/2020
<b>Febuxostat</b> tablets Adenuric® 1153/16	Prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of Tumour Lysis Syndrome (TLS).	Routinely available in line with national guidance	13/06/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Fentanyl</b> transdermal system  <b>Ionsys®</b>  1207/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1207_16_fentanyl_ionsys/fentanyl_ionsys_Non_Submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1207_16_fentanyl_ionsys/fentanyl_ionsys_Non_Submission</a>	Management of acute moderate to severe post-operative pain in adult patients	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Ferric maltol</b> capsules  <b>Feraccru®</b>  1202/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1202_16_ferric_maltol_Feraccru/ferric_maltol_Feraccru</a>	Treatment of iron deficiency anaemia (IDA) in adult patients with inflammatory bowel disease (IBD).	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Fluticasone and Formoterol</b> breath actuated inhaler  <b>Flutiform k-haler®</b>  SMC2016  <a href="https://www.scottishmedicines.org.uk/media/3468/fluticasone-propionate-flutiform-k-haler-abb-final-may-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3468/fluticasone-propionate-flutiform-k-haler-abb-final-may-2018-for-website.pdf</a>	for the regular treatment of asthma where the use of a combination product [an inhaled corticosteroid (ICS) and a long-acting $\beta$ 2-agonist (LABA)] is appropriate: - For patients not adequately controlled with ICS as 'as required' inhaled short-acting $\beta$ 2-agonist or - For patients already adequately controlled on both ICS and a LABA	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	11/06/2018
<b>Fluticasone, Umeclidinium, Vilanterol</b> inhalation powder  <b>Trelegy® Ellipta®</b>  1303/18  <a href="http://www.scottishmedicines.org.uk/files/advice/fluticasone_furoate_Trelegy_Ellipta_Abbreviated_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/fluticasone_furoate_Trelegy_Ellipta_Abbreviated_FINAL_Jan_2018_for_website.pdf</a>	Maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting $\beta$ 2-agonist.	Routinely available in line with national guidance	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Follitropin delta</b> injection Rekovelletm 1269/17	Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies such as an in vitro fertilisation or intracytoplasmic sperm injection cycle.  <a href="http://www.scottishmedicines.org.uk/files/advice/follitropin_Rekovelletm_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/follitropin_Rekovelletm_Non_Sub_FINAL_July_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Fosaprepitant</b> infusion Ivemend SMC2108	prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in paediatric patients aged 6 months to 17 years. Fosaprepitant is given as part of a combination therapy.	Routinely available in line with national guidance	25/02/2019
<b>Fosfomycin trometamol</b> granules for oral solution Monuril <sup>®</sup> 1163/16	Treatment of acute lower uncomplicated urinary tract infections, caused by pathogens sensitive to fosfomycin in adult and adolescent females and prophylaxis in diagnostic and surgical transurethral procedures.  <a href="http://www.scottishmedicines.org.uk/files/advice/fosfomycin_trometamol_Monuril_Abbreviated_FINAL_June_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/fosfomycin_trometamol_Monuril_Abbreviated_FINAL_June_2016_for_website.pdf</a>	Routinely available in line with local or regional guidance	10/10/2016
<b>Fremanezumab</b> injection Ajovy <sup>®</sup> SMC2226	Prophylaxis of migraine in adults who have at least four migraine days per month.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  10/08/2020	24/02/2020

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Fulvestrant</b> injection <b>Faslodex®</b> 1294/17	Treatment of oestrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.	Not routinely available as not recommended for use in NHSScotland	11/12/2017
<b>Fulvestrant</b> injection <b>Faslodex®</b> 114/04	Treatment of postmenopausal women with oestrogen receptor positive, locally advanced or metastatic breast cancer for disease relapse on or after adjuvant anti-oestrogen therapy, or disease progression on therapy with an anti-oestrogen.	Routinely available in line with local or regional guidance	22/02/2016
<b>Gemtuzumab ozogamicin</b> infusion <b>Mylotarg®</b> SMC2089	Combination therapy with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo CD33 positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL).	Routinely available in line with local or regional guidance	08/10/2018
<b>Genvoya®</b> tablets <b>Genvoya®</b> 1142/16	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35kg) infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir.	Routinely available in line with national guidance	13/06/2016



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Glecaprevir with Pibrentasvir</b> tablets Maviret® 1278/17	Treatment of chronic hepatitis C virus (HCV) infection in adults	Routinely available in line with national guidance	11/12/2017
<b>Glibenclamide</b> oral suspension Amglidia® SMC2237	Treatment of neonatal diabetes mellitus, for use in newborns, infants and children.	Not routinely available as not recommended for use in NHSScotland	07/10/2019
<b>Glycerol Phenylbutyrate</b> oral liquid Ravicti® 1342/18	For use as adjunctive therapy for chronic management of adult and paediatric patients $\geq 2$ months of age with urea cycle disorders (UCDs) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.  <a href="https://www.scottishmedicines.org.uk/media/3649/glycerol-phenylbutyrate-ravict-final-july-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3649/glycerol-phenylbutyrate-ravict-final-july-2018-for-website.pdf</a>	Routinely available in line with national guidance	13/08/2018
<b>Glycopyrronium</b> oral solution Sialanar® 1254/17	Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.  <a href="http://www.scottishmedicines.org.uk/files/advice/glycopyrronium_bromide_Sialanar_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/glycopyrronium_bromide_Sialanar_Abbreviated_FINAL_June_2017_for_website.pdf</a>	Routinely available in line with national guidance	23/10/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Golimumab</b> injection <b>Simponi®</b> 1199/16	In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children with a body weight of at least 40 kg, who have responded inadequately to previous therapy with methotrexate.  <a href="http://www.scottishmedicines.org.uk/files/advice/golimumab_Simponi_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/golimumab_Simponi_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<b>Golimumab</b> sub-cutaneous injection <b>Simponi®</b> 1124/16	Treatment of adults with severe, active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence, who have had an inadequate response to, or are intolerant to non-steroidal anti-inflammatory drugs (NSAIDs).	Routinely available in line with national guidance	22/02/2016
<b>Golimumab</b> injection <b>Simponi®</b> SMC2203	In combination with methotrexate for the treatment of polyarticular juvenile idiopathic arthritis in children 2 years of age and older who have responded inadequately to previous therapy with methotrexate	Not routinely available as not recommended for use in NHSScotland	10/06/2019
<b>Guanfacine</b> prolonged-release tablets <b>Intuniv®</b> 1123/16	Treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 yrs old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1123_16_guanfacine_hydrochloride_Intuniv/Briefing_note_guanfacine_hydrochloride_Int</a>	Routinely available in line with national guidance	18/04/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Guselkumab</b> injection	Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Routinely available in line with local or regional guidance	09/12/2019
<b>Tremfya®</b>  1340/18		31/12/2018	
<b>Human alpha1-proteinase inhibitor</b> infusion	Maintenance treatment, to slow the progression of emphysema in adults with documented severe alpha1-proteinase inhibitor (A1-PI) deficiency.	Not routinely available as not recommended for use in NHSScotland	22/08/2016
<b>Respreeza®</b>  1157/16			
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1157_16_human_alpha_1_proteinase_inhibitor_Respreeza/human_alpha_1_proteinase">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1157_16_human_alpha_1_proteinase_inhibitor_Respreeza/human_alpha_1_proteinase</a>		
<b>Hydrocortisone</b> modified-release tablets	Treatment of adrenal insufficiency in adults	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Plenadren®</b>  848/12			
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/848_12_hydrocortisone_Plenadren/hydrocortisone_Plenadren</a>		
<b>Hydrocortisone</b> granules in capsules	Replacement therapy of adrenal insufficiency in infants, children and adolescents (from birth to <18 years old).	Routinely available in line with national guidance	25/02/2019
<b>Alkindi®</b>  SMC2088			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Hyoscine hydrobromide</b> tablets	Antispasmodic for irritable bowel syndrome		22/08/2016
<b>Ibrutinib</b> capsules <b>Imbruvica®</b> 1258/17	In combination with bendamustine and rituximab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Ibrutinib</b> capsules <b>Imbruvica®</b> 1151/16	Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	Routinely available in line with local or regional guidance	24/04/2017
<b>Ibrutinib</b> tablets <b>Imbruvica®</b> SMC2244	In combination with obinutuzumab for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia.	Not routinely available as not recommended for use in NHSScotland	09/12/2019

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1258\\_17\\_ibrutinib\\_Imbruvica/ibrutinib\\_Imbruvica\\_Non-submission](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1258_17_ibrutinib_Imbruvica/ibrutinib_Imbruvica_Non-submission)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ibrutinib</b> capsules Imbruvica® 1289/17	As a single agent for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (who do not have 17p deletion or TP53 mutation).	Not routinely available as not recommended for use in NHSScotland	11/12/2017
<b>Ibrutinib</b> hard capsules Imbruvica® 1151/16	Treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1151_16_ibrutinib_Imbruvica_CLL/ibrutinib_Imbruvica_CLL">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1151_16_ibrutinib_Imbruvica_CLL/ibrutinib_Imbruvica_CLL</a>	Routinely available in line with local or regional guidance	22/08/2016
<b>Ibrutinib</b> tablets Imbruvica® SMC2245	As a single agent for the treatment of adult patients with Waldenström's macroglobulinaemia who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy.	Not routinely available as not recommended for use in NHSScotland	09/12/2019
<b>Ibrutinib</b> hard capsules Imbruvica® 1150/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1150_16_ibrutinib_Imbruvica_MCL/ibrutinib_Imbruvica_MCL">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1150_16_ibrutinib_Imbruvica_MCL/ibrutinib_Imbruvica_MCL</a>	Routinely available in line with local or regional guidance	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Icatibant acetate</b> injection, pre-filled syringe <b>Firazyr®</b> 1332/18	Symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adolescents and children aged 2 years and older, with C1-esterase-inhibitor deficiency.	Not routinely available as local implementation plans are being developed or ADTC is waiting for further advice from local clinical experts - Decision expected by:  21/08/2018	11/06/2018
<b>Idarucizumab</b> injection/infusion <b>Praxbind®</b> 1178/16	Reversal of anticoagulation effect of dabigatran in adults when rapid reversal is required for emergency surgery/urgent procedures or in life-threatening or uncontrolled bleeding	Routinely available in line with national guidance	10/10/2016
<b>Idebenone</b> tablets <b>Raxone®</b> 1226/17	Treatment of visual impairment in adolescent and adult patients with Leber's Hereditary Optic Neuropathy (LHON).	Routinely available in line with national guidance	19/06/2017
<b>Idelalisib</b> tablets <b>Zydelig®</b> 1212/16	In combination with ofatumumab for the treatment of adult patients with chronic lymphocytic leukaemia who have received at least one prior therapy, or first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies.	Not routinely available as not recommended for use in NHSScotland	12/12/2016

[http://www.scottishmedicines.org.uk/files/advice/idarucizumab\\_Praxbind\\_FINAL\\_August\\_2016\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/idarucizumab_Praxbind_FINAL_August_2016_for_website.pdf)

[http://www.scottishmedicines.org.uk/files/advice/idebenone\\_Raxone\\_FINAL\\_April\\_2017\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/idebenone_Raxone_FINAL_April_2017_for_website.pdf)

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1212\\_16\\_idelalisib\\_Zydelig/idelalisib\\_Zydelig\\_Non\\_Submission](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1212_16_idelalisib_Zydelig/idelalisib_Zydelig_Non_Submission)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Imiquimod</b> cream Zyclara® SMC2211	Topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate.	Routinely available in line with national guidance	09/12/2019
<b>Inotersen</b> injection Tegsedi® SMC2188	Treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).	Routinely available in line with national guidance	12/08/2019
<b>Inotuzomab ozogamicin</b> infusion BESPONSA® 1328/18	Monotherapy for the treatment of adults with relapsed or refractory CD22-positive B cell precursor acute lymphoblastic leukaemia (ALL). Adult patients with Philadelphia chromosome positive relapsed or refractory B cell precursor ALL should have failed treatment with at least one tyrosine kinase inhibitor.	Routinely available in line with local or regional guidance	11/06/2018
<b>Insulin aspart</b> injection Fiasp® 1227/17	Treatment of diabetes mellitus in adults.	Routinely available in line with national guidance	24/04/2017
<a href="http://www.scottishmedicines.org.uk/files/advice/insulin_aspart_Fiasp_Abbreviated_FINAL_March_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/insulin_aspart_Fiasp_Abbreviated_FINAL_March_2017_for_website.pdf</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Insulin degludec</b> pre-filled pen, cartridge Tresiba® 856/13  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/856_13_insulin_degludec_Tresiba/insulin_degludec_Tresiba_2nd_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/856_13_insulin_degludec_Tresiba/insulin_degludec_Tresiba_2nd_Resubmission</a>	Treatment of diabetes mellitus in adults	Routinely available in line with local or regional guidance	22/08/2016
<b>Insulin detemir</b> injection Levemir® 1126/16	Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.	Routinely available in line with national guidance	26/04/2016
<b>Insulin Glargine 300 units/ml</b> pre-filled pen Toujeo® 1078/15  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1078_15_insulin_glargine_Toujeo/insulin_glargine_Toujeo_ABB</a>	Treatment of type 1 or type 2 diabetes mellitus in adults aged 18 years and above.	Routinely available in line with local or regional guidance	12/12/2016
<b>Insulin glargine plus Lixisenatide</b> injection Suliqua® SMC2235	In combination with metformin for the treatment of adults with type 2 diabetes mellitus, to improve glycaemic control when this has not been provided by metformin alone or metformin combined with another oral glucose-lowering medicinal product or with basal insulin.	Routinely available in line with national guidance	06/07/2020



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Ipilimumab</b> infusion Yervoy® SMC2094</p>	<p>Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adolescents 12 years of age and older.</p>	<p>Routinely available in line with national guidance</p>	<p>18/12/2018</p>
<p><b>Iron (III) isomaltoside 1000</b> injection Diafer® 1177/16</p>	<p>The treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>10/10/2016</p>
<p><a href="http://www.scottishmedicines.org.uk/files/advice/iron_isomaltoside_1000_Diafer_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/iron_isomaltoside_1000_Diafer_FINAL_August_2016_for_website.pdf</a></p>			
<p><b>Iron III isomaltoside 1000</b> injection Diafer® 1177/16</p>	<p>Treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used.</p>	<p>Routinely available in line with national guidance</p>	<p>20/02/2017</p>
<p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1177_16_iron_isomaltoside_1000_Diafer/iron_III_isomaltoside_1000_Diafer_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1177_16_iron_isomaltoside_1000_Diafer/iron_III_isomaltoside_1000_Diafer_Resub</a></p>			
<p><b>Isavuconazole</b> infusion, hard capsules Cresemba® 1129/16</p>	<p>in adults for the treatment of: -invasive aspergillosis -mucormycosis in patients for whom amphotericin B is inappropriate</p>	<p>Routinely available in line with national guidance</p>	<p>18/04/2016</p>
<p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note">http://www.scottishmedicines.org.uk/SMC_Advice/Briefing_Note/Briefing_Note</a></p>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ivacaftor</b> granules <b>Kalydeco®</b> 1134/16	Treatment of children with cystic fibrosis (CF) aged 2 years and older and weighing less than 25kg who have one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Ivacaftor</b> tablets <b>Kalydeco®</b> 1193/16	Treatment of patients with cystic fibrosis (CF) aged 18 years and older who have an R117H mutation in the CF transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Ixazomib</b> capsules <b>Ninlaro®</b> SMC2099	In combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.	Not routinely available as not recommended for use in NHSScotland	13/08/2018
<b>Ixekizumab</b> injection <b>Taltz®</b> 1223/17	Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Routinely available in line with national guidance	24/04/2017

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1193\\_16\\_ivacaftor\\_Kalydeco/ivacaftor\\_Kalydeco](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1193_16_ivacaftor_Kalydeco/ivacaftor_Kalydeco)

<https://www.scottishmedicines.org.uk/medicines-advice/ixazomib-ninlaro-non-submission-smc2099/>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ixekizumab</b> injection in pre-filled syringe Taltz® SMC2097	Alone or in combination with methotrexate, is indicated for the treatment of active psoriatic arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drug (DMARD) therapies.	Routinely available in line with local or regional guidance  31/12/2018	25/02/2019
<b>Lacosamide</b> syrup, iv infusion Vimpat® 1324/18	Monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<b>Lacosamide</b> tablets, infusion Vimpat® 1301/18	As adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy.	Routinely available in line with national guidance	10/06/2019
<b>Lacosamide</b> tablets, infusion, syrup Vimpat® 1231/17	As monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adult and adolescent (16-18 years) patients with epilepsy.	Not routinely available as not recommended for use in NHSScotland	24/04/2017

<https://www.scottishmedicines.org.uk/medicines-advice/lacosamide-50mg-100mg-150mg-200mg-tablets-10mgml-syrup-and-10mgml-solution-for-i>

[http://www.scottishmedicines.org.uk/files/advice/lacosamide\\_Vimpat\\_Abbreviated\\_FINAL\\_Jan\\_2018\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/lacosamide_Vimpat_Abbreviated_FINAL_Jan_2018_for_website.pdf)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Lanadelumab</b> sub-cutaneous injection Takhyzyro® SMC2206	For the routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older	Routinely available in line with national guidance	09/12/2019
<b>Latanoprost &amp; Timolol</b> preservative free eye drops Fixapost® SMC2159	Reduction of intraocular pressure (IOP) in patients with open angle glaucoma and ocular hypertension who are insufficiently responsive to topical beta-blockers or prostaglandin analogues.	Routinely available in line with national guidance	10/06/2019
<b>Ledipasvir and Sofosbuvir</b> tablet Harvoni® 1343/18	Treatment of chronic hepatitis C (CHC) in adolescents aged 12 to <18 years.	Routinely available in line with national guidance  21/08/2018	11/06/2018
<b>Lenalidomide</b> capsules Revlimid® 1211/16	Treatment of adult patients with relapsed or refractory mantle cell lymphoma.	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1211_16_lenalidomide_Revlimid/lenalidomide_Revlimid_non_submission</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Lenalidomide</b> capsules Revlimid® SMC2217	As combination therapy with bortezomib and dexamethasone for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.	Not routinely available as not recommended for use in NHSScotland	12/08/2019
<b>Lenalidomide</b> hard capsules Revlimid® SMC2125	Monotherapy for the maintenance treatment of adult patients with newly diagnosed multiple myeloma who have undergone autologous stem cell transplantation.	Not routinely available as not recommended for use in NHSScotland	08/10/2018
<b>Lenvatinib</b> capsule Kisplyx® SMC2199	In combination with everolimus for the treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior vascular endothelial growth factor (VEGF)-targeted therapy	Routinely available in line with local or regional guidance	09/12/2019
<b>Lenvatinib</b> capsules Lenvima® 1179/16	Treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI).	Routinely available in line with local or regional guidance	10/10/2016
<a href="http://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/lenvatinib_Lenvima_FINAL_Sept_2016_amended_30.09.16_for_website.pdf</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Lenvatinib</b> capsules Lenvima® SMC2138	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy.	Routinely available in line with local or regional guidance	29/04/2019
<b>Letermovir</b> tablets Prevymis® SMC1338/18	Prophylaxis of cytomegalovirus (CMV) reactivation and disease in adult CMV-seropositive recipients [R+] of an allogeneic haematopoietic stem cell transplant (HSCT).	Routinely available in line with national guidance	29/04/2019
<b>Levofloxacin</b> nebuliser solution Quinsair® 1162/16	Management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.	Routinely available in line with national guidance	22/08/2016
<b>Levonorgestrel</b> intrauterine delivery system Kyleena® 1299/18	Contraception for up to 5 years.	Routinely available in line with national guidance	26/02/2018
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1162_16_levofloxacin_Quinsair/levofloxacin_Quinsair">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1162_16_levofloxacin_Quinsair/levofloxacin_Quinsair</a> <a href="http://www.scottishmedicines.org.uk/files/advice/levonorgestrel_Kyleena_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/levonorgestrel_Kyleena_FINAL_Jan_2018_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Liposomal Daunorubicin/Cytarabine</b> infusion  Vyxeos®  SMC2130	The treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia (AML) or AML with myelodysplasia-related changes.	Routinely available in line with local or regional guidance	29/04/2019
<b>Liposomal Irinotecan</b> infusion  Onivyde®  1217/17	Treatment of metastatic adenocarcinoma of the pancreas, in combination with fluorouracil(5-FU) and leucovorin (folinic acid), in adult patients who have progressed following gemcitabine based therapy.	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Liraglutide</b> injection  Saxenda®  1247/17	As an adjunct to a reduced-calorie diet and increased physical activity for weight management in adult patients with an initial Body Mass Index of $\geq 30\text{kg/m}^2$ (obese), or $\geq 27\text{kg/m}^2$ to $< 30\text{kg/m}^2$ (overweight) in the presence of at least one weight-related comorbidity such as dysglycaemia (pre-diabetes or type 2 diabetes mellitus), hypertension, dyslipidaemia or obstructive sleep apnoea.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1247_17_liraglutide_Saxenda/liraglutide_Saxenda_Non_Sub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1247_17_liraglutide_Saxenda/liraglutide_Saxenda_Non_Sub</a>	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Liraglutide</b> injection  Victoza®  1192/16	As monotherapy for the treatment of adults with type 2 diabetes mellitus to achieve glycaemic control when diet and exercise alone do not provide adequate glycaemic control in patients for whom use of metformin is considered inappropriate due to intolerance or contraindications.  <a href="http://www.scottishmedicines.org.uk/files/advice/liraglutide_Victoza_Non_Sub_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/liraglutide_Victoza_Non_Sub_FINAL_August_2016_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Lorlatinib</b> tablets Lorviqua® SMC2239	Monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: - alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or - crizotinib and at least one other ALK TKI	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	06/07/2020
<b>Lumacaftor and Ivacaftor</b> tablets, granules Orkambi® SMC2182	Treatment of cystic fibrosis in patients aged 6 years and older (tablets) and aged 2 to 5 years (granules) who are homozygous for the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHSScotland	12/08/2019
<b>Lumacaftor with ivacaftor</b> tablets Orkambi® 1136/16	Treatment of cystic fibrosis (CF) in patients aged 12 years and older who are homozygous for the F508del mutation in the CF transmembrane conductance regulator (CFTR) gene.	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Lurasidone</b> tablets Latuda® SMC 994/14	Treatment of schizophrenia in adults aged 18 years and over	Routinely available in line with local or regional guidance	23/10/2017
<a href="http://www.scottishmedicines.org.uk/files/advice/lurasidone_Latuda_FINAL_Sept_2014_amended_15.09.14_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/lurasidone_Latuda_FINAL_Sept_2014_amended_15.09.14_for_website.pdf</a>			



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Lustrombopag</b> tablets Mulpleo® SMC2227	The treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures	Routinely available in line with national guidance	09/12/2019
<b>Lutetium oxodotreotide</b> infusion Lutathera® 1337/18	Treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.	Routinely available in line with local or regional guidance	13/08/2018
<b>Magnesium glycerophosphate</b> chewable tablet Neomag® 1267/17	<p>as an oral magnesium supplement for the treatment of patients with chronic magnesium loss or hypomagnesaemia as diagnosed by a doctor. Magnesium glycerophosphate is also indicated for adult patients with hypomagnesaemia due to the concomitant administration of loop and thiazide diuretics or other drugs which cause hypomagnesaemia.</p> <p><a href="https://www.scottishmedicines.org.uk/media/3557/lutetium-177lu-oxodotreotide-lutathera-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3557/lutetium-177lu-oxodotreotide-lutathera-final-june-2018-for-website.pdf</a></p>	Routinely available in line with national guidance	23/10/2017
<b>Maraviroc</b> oral solution, tablets Celsentri® 1282/17	<p>In combination with other antiretroviral medicinal products for treatment-experienced adolescents and children of 2 years and older and weighing at least 10kg infected with only CCR5-tropic HIV-1 detectable.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/magnesium_glycerophosphate_Neomag_Abb_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/magnesium_glycerophosphate_Neomag_Abb_FINAL_August_2017_for_website.pdf</a></p>	Not routinely available as not recommended for use in NHSScotland	23/10/2017
	<p><a href="http://www.scottishmedicines.org.uk/files/advice/maraviroc_Celsentri_Non_Sub_FINAL_Sept_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/maraviroc_Celsentri_Non_Sub_FINAL_Sept_2017_for_website.pdf</a></p>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Mefenamic acid</b> tablets Ponstan® and generic N/A</p>	Dysmenorrhoea and heavy menstrual bleeding	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	28/08/2017
<p><b>Melatonin</b> prolonged-release tablets Slenyto® SMC2168</p>	Treatment of insomnia in children and adolescents aged 2 to 18 years with autism spectrum disorder and / or Smith-Magenis syndrome, where sleep hygiene measures have been insufficient.	Not routinely available as not recommended for use in NHSScotland	07/10/2019
<p><b>Mepolizumab</b> injection Nucala® 1149/16</p>	Add-on treatment for severe refractory eosinophilic asthma in adult patients.	Routinely available in line with local or regional guidance	13/06/2016
<p><b>Mepolizumab</b> injection Nucala® SMC2139</p>	as an add-on treatment for severe refractory eosinophilic asthma in adolescents and children aged 6 years and older	Routinely available in line with national guidance	29/04/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Mercaptamine bitartrate</b> MR capsules Procysbi® 1272/17</p>	<p>For the treatment of proven nephropathic cystinosis.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>11/12/2017</p>
<p><b>Metformin</b> MR tablets Glucophage SR® 1308/18</p>	<p>Reduction in the risk or delay of the onset of type 2 diabetes mellitus in adult, overweight patients with impaired glucose tolerance and/or impaired fasting glucose, and/or increased HbA1C who are: - at high risk for developing overt type 2 diabetes mellitus and - still progressing towards type 2 diabetes mellitus despite implementation of intensive lifestyle change for 3 to 6 months.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/metformin_hydrochloride_Glucophage_Non_Sub_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/metformin_hydrochloride_Glucophage_Non_Sub_FINAL_Dec_2017_for_website.pdf</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>26/02/2018</p>
<p><b>Mexiletine</b> capsules Namuscla® SMC2241</p>	<p>Symptomatic treatment of myotonia in adult patients with non-dystrophic myotonic disorders.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>06/07/2020</p>
<p><b>Micronised progesterone</b> vaginal capsules Utrogestan® 935/13</p>	<p>In women for supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/micronised_progesterone_Utrogestan_Vaginal_FINAL_April_2017_Amended_12.04.17_for_webs">http://www.scottishmedicines.org.uk/files/advice/micronised_progesterone_Utrogestan_Vaginal_FINAL_April_2017_Amended_12.04.17_for_webs</a></p>	<p>Routinely available in line with national guidance</p>	<p>19/06/2017</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Midazolam maleate</b> oromucosal solution</p> <p>Epistatus® PFS</p> <p>1279/17</p>	<p>Treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years</p>	<p>Routinely available in line with national guidance</p>	<p>01/01/2018</p>
<p><b>Midostaurin</b> capsules</p> <p>Rydapt®</p> <p>1330/18</p>	<p>In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FMS like tyrosine kinase 3 (FLT3) mutation-positive.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>11/06/2018</p>
<p><b>Midostaurin</b> capsules</p> <p>Rydapt®</p> <p>SMC2100</p>	<p>Monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>13/08/2018</p>
<p><b>Migalastat</b> capsules</p> <p>Galafold®</p> <p>1196/16</p>	<p>Long-term treatment of adults and adolescents aged 16 years and older with a confirmed diagnosis of Fabry disease (<math>\alpha</math>-galactosidase A deficiency) and who have an amenable mutation.</p>	<p>Routinely available in line with national guidance</p>	<p>12/12/2016</p>
	<p><a href="https://www.scottishmedicines.org.uk/medicines-advice/midostaurin-rydapt-non-submission-smc2100/">https://www.scottishmedicines.org.uk/medicines-advice/midostaurin-rydapt-non-submission-smc2100/</a></p>		
	<p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1196_16_migalastat_Galafold/migalastat_Galafold</a></p>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>N/A</b> melt-in cream  Anthelios® XL SPF 50  Formulary appeal</p>	<p>Skin protection against UVA and UVB rays</p>	<p>Routinely available in line with local or regional guidance</p>	<p>18/04/2016</p>
<p><b>Naldemedine</b> tablets  Rizmoic®  SMC2242</p>	<p>Treatment of opioid induced constipation (OIC) in adult patients who have previously been treated with a laxative.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>06/07/2020</p>
<p><b>Naltrexone and Bupropion</b> MR tablets  Mysimba®  SMC2086</p>	<p>As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥18 years) with an initial Body Mass Index (BMI) of ≥ 30 kg/m<sup>2</sup> (obese), or ≥ 27 kg/m<sup>2</sup> to &lt; 30 kg/m<sup>2</sup> (overweight) in the presence of one or more weight-related co-morbidities (e.g., type 2 diabetes, dyslipidaemia, or controlled hypertension)</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>11/06/2018</p>
<p><b>Naproxen</b> effervescent tablets  Stirlescent®  1154/16</p>	<p>Treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute musculoskeletal disorders, dysmenorrhoea and acute gout in adults</p>	<p>Routinely available in line with national guidance</p>	<p>13/06/2016</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Necitumumab</b> infusion <b>Portrazza®</b> 1184/16</p>	<p>In combination with gemcitabine and cisplatin chemotherapy for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing squamous non-small cell lung cancer who have not received prior chemotherapy for this condition.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1184_16_necitumumab_Portrazza/necitumumab_Portrazza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1184_16_necitumumab_Portrazza/necitumumab_Portrazza</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>22/08/2016</p>
<p><b>Nepafenac</b> eye drops <b>Nevanac®</b> 1228/17</p>	<p>Reduction in the risk of postoperative macular oedema associated with cataract surgery in diabetic patients</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/nepafenac_Nevanac_Abbreviated_FINAL_March_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nepafenac_Nevanac_Abbreviated_FINAL_March_2017_for_website.pdf</a></p>	<p>Routinely available in line with national guidance</p>	<p>24/04/2017</p>
<p><b>Netupitant with Palonosetron</b> capsules <b>Akynzeo®</b> 1109/15</p>	<p>Prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in adult patients.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>22/02/2016</p>
<p><b>Nilotinib</b> hard capsules <b>Tasigna®</b> 1325/18</p>	<p>-paediatric patients with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukaemia (CML) in the chronic phase -paediatric patients with Philadelphia chromosome positive CML in chronic phase with resistance or intolerance to prior therapy including imatinib</p> <p><a href="https://www.scottishmedicines.org.uk/medicines-advice/nilotinib-150mg-and-200mg-hard-capsules-tasigna-non-submission-132518/">https://www.scottishmedicines.org.uk/medicines-advice/nilotinib-150mg-and-200mg-hard-capsules-tasigna-non-submission-132518/</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>23/04/2018</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Niraparib tosylate monohydrate</b> capsules Zejula® 1341/18	As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy  <a href="https://www.scottishmedicines.org.uk/media/3650/niraparib-tosylate-monohydrate-zejula-final-july-2018-amended-240718-for-website.pdf">https://www.scottishmedicines.org.uk/media/3650/niraparib-tosylate-monohydrate-zejula-final-july-2018-amended-240718-for-website.pdf</a>	Routinely available in line with local or regional guidance	13/08/2018
<b>Nivolumab</b> infusion Opdivo® 1144/16	Treatment of locally advanced or metastatic squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1144_16_nivolumab_Opdivo_for_metastatic_squamous_NSCLC/nivolumab_Opdivo_for">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1144_16_nivolumab_Opdivo_for_metastatic_squamous_NSCLC/nivolumab_Opdivo_for</a>	Routinely available in line with local or regional guidance	22/08/2016
<b>Nivolumab</b> infusion Opdivo® 1188/16	As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma/nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1188_16_nivolumab_Opdivo_for_renal_cell_carcinoma/nivolumab_Opdivo</a>	Not routinely available as not recommended for use in NHSScotland	12/12/2016
<b>Nivolumab</b> infusion Opdivo® 1261/17	As monotherapy, for the treatment of squamous cell cancer of the head and neck (SCCHN) in adults progressing on or after platinum-based therapy.  <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_August_2017_for_website.pdf</a>	Routinely available in line with local or regional guidance	23/10/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Nivolumab</b> infusion Opdivo® SMC2153</p>	<p>In combination with ipilimumab for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (RCC).</p>	<p>Routinely available in line with local or regional guidance</p>	<p>10/06/2019</p>
<p><b>Nivolumab</b> infusion Opdivo® 1285/18</p>	<p>Nivolumab as monotherapy is indicated for the treatment of locally advanced unresectable or metastatic urothelial carcinoma in adults after failure of prior platinum-containing therapy.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Dec_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Dec_2017_for_website.pdf</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>26/02/2018</p>
<p><b>Nivolumab</b> infusion Opdivo® SMC2112</p>	<p>Monotherapy for the adjuvant treatment of adults with melanoma with involvement of lymph nodes or metastatic disease who have undergone complete resection.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>10/12/2018</p>
<p><b>Nivolumab</b> infusion Opdivo® 1188/16</p>	<p>As monotherapy for the treatment of advanced renal cell carcinoma after prior therapy in adults.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_RESUBMISSION_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_RESUBMISSION_FINAL_May_2017_for_website.pdf</a></p>	<p>Routinely available in line with local or regional guidance</p>	<p>19/06/2017</p>



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Nivolumab</b> infusion Opdivo® 1180/16  <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Sept_2016_FINAL_amended_150916_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_FINAL_Sept_2016_FINAL_amended_150916_for_website.pdf</a>	Treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.	Routinely available in line with local or regional guidance	10/10/2016
<b>Nivolumab</b> infusion Opdivo® 1120/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/Briefing_note_nivolumab_Opdivo</a>	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Not routinely available as not recommended for use in NHSScotland	18/04/2016
<b>Nivolumab</b> infusion Opdivo® 1120/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/nivolumab_Opdivo_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1120_16_nivolumab_Opdivo/nivolumab_Opdivo_Resubmission</a>	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Routinely available in line with local or regional guidance	22/08/2016
<b>Nivolumab</b> infusion Opdivo® 1240/17  <a href="http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_cHL_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/nivolumab_Opdivo_cHL_FINAL_June_2017_for_website.pdf</a>	Treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) after autologous stem cell transplant (ASCT) and treatment with brentuximab vedotin.	Routinely available in line with local or regional guidance	28/08/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Nivolumab</b> infusion Opdivo® 1187/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1187_16_nivolumab_Opdivo_with_ipilimumab_for_melanoma/nivolumab_Opdivo">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1187_16_nivolumab_Opdivo_with_ipilimumab_for_melanoma/nivolumab_Opdivo</a>	In combination with ipilimumab for the treatment of advanced (unresectable or metastatic) melanoma in adults.	Routinely available in line with local or regional guidance	12/12/2016
<b>Nusinersen</b> injection Spinraza® SMC 1318/18	Treatment of type II and III (later onset) 5q spinal muscular atrophy (SMA)	Routinely available in line with national guidance	12/08/2019
<b>Nusinersen</b> injection Spinraza® 1318/18	Treatment of 5q spinal muscular atrophy (SMA).	Routinely available in line with national guidance	11/06/2018
<b>Obeticholic acid</b> tablets Ocaliva® 1232/17  <a href="http://www.scottishmedicines.org.uk/files/advice/obeticholic_acid_Ocaliva_FINAL_May_2017_Amended_170517_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/obeticholic_acid_Ocaliva_FINAL_May_2017_Amended_170517_for_website.pdf</a>	Primary biliary cholangitis (alsoknown as primary biliary cirrhosis) in combination with ursodeoxycholic acid in adults with an inadequate response to ursodeoxycholic acid or as monotherapy in adults unable to tolerate ursodeoxycholic acid	Routinely available in line with local or regional guidance	19/06/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Obinutuzumab</b> infusion Gazyvaro® 1219/17`	Obinutuzumab in combination with bendamustine followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to six months after treatment with rituximab or a rituximab-containing regimen.	Routinely available in line with local or regional guidance	24/04/2017
<b>Obinutuzumab</b> infusion Gazyvaro® SMC2015	In combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.	Not routinely available as not recommended for use in NHSScotland	08/10/2018
<b>Obinutuzumab</b> infusion Gazyvaro® 1286/18	Obinutuzumab in combination with chemotherapy, followed by obinutuzumab maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma.	Not routinely available as not recommended for use in NHSScotland	26/02/2018
	<a href="http://www.scottishmedicines.org.uk/files/advice/obinutuzumab_Gazyvaro_FINAL_Dec_2018_Amended_14.12.17_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/obinutuzumab_Gazyvaro_FINAL_Dec_2018_Amended_14.12.17_for_website.pdf</a>		
<b>Ocrelizumab</b> infusion Ocrevus® SMC2121	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.	Routinely available in line with local or regional guidance  01/06/2019	09/12/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ocrelizumab</b> infusion Ocrevus® 1344/18	Treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.  <a href="https://www.scottishmedicines.org.uk/media/3603/ocrelizumab-ocrevus-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3603/ocrelizumab-ocrevus-final-june-2018-for-website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	13/08/2018
<b>Ocrelizumab</b> infusion Ocrevus® SMC2223	Treatment of adult patients with early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity.	Routinely available in line with local or regional guidance	06/07/2020
<b>Oestrogens, conjugated, bazedoxifene acetate</b> modified-release tablets Duavive® 1220/17	Treatment of oestrogen deficiency symptoms in postmenopausal women with a uterus (with at least 12 months since the last menses) for whom treatment with progestin-containing therapy is not appropriate.	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Ofatumumab</b> infusion Arzerra® 1237/17	Treatment of adult patients with relapsed CLL in combination with fludarabine and cyclophosphamide.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1220_17_oestrogens_conjugated_Duavive/oestrogens_conjugated_Duavive_Non_Sub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1220_17_oestrogens_conjugated_Duavive/oestrogens_conjugated_Duavive_Non_Sub</a>	Not routinely available as not recommended for use in NHSScotland	24/04/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/ofatumumab_Arzerra_Non_Sub_FINAL_March_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ofatumumab_Arzerra_Non_Sub_FINAL_March_2017_for_website.pdf</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Olaparib</b> capsules Lynparza® 1047/15	Monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed BRCA-mutated (germline and/or somatic) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response or partial response) to platinum-based chemotherapy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1047_15_olaparib_Lynparza/olaparib_Lynparza_Resubmission</a>	Routinely available in line with local or regional guidance	12/12/2016
<b>Olaparib</b> tablets Lynparza® SMC2209	Maintenance treatment of adult patients with advanced (FIGO stages III and IV) BRCA1/2-mutated (germline and/or somatic) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy.	Routinely available in line with local or regional guidance	09/12/2019
<b>Olaratumab</b> infusion Lartruvo® 1273/17	In combination with doxorubicin for the treatment of adult patients with advanced soft-tissue sarcoma who are not amenable to curative treatment with surgery or radiotherapy and who have not been previously treated with doxorubicin.	Routinely available in line with local or regional guidance	11/12/2017
<b>Opicapone</b> capsules Ongentys® 1281/17	Adjunctive therapy to preparations of levodopa / DOPA decarboxylase inhibitors in adult patients with Parkinson's disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations  <a href="http://www.scottishmedicines.org.uk/files/advice/opicapone_Ongentys_Non_Sub_FINAL_Sept_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/opicapone_Ongentys_Non_Sub_FINAL_Sept_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	23/10/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Osetamivir</b> powder for oral suspension  <b>Tamiflu®</b>  1127/16	Treatment of influenza in children aged <1 year including full term neonates who present with symptoms typical of influenza, when influenza virus is circulating in the community. Efficacy has been demonstrated when treatment is initiated within two days of first onset of symptoms.	Routinely available in line with national guidance	26/04/2016
<b>Osimertinib</b> tablets  <b>Tagrisso®</b>  1214/17	Treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small-cell lung cancer (NSCLC).	Routinely available in line with local or regional guidance	20/02/2017
<b>Osimertinib</b> tablet  <b>Tagrisso®</b>  SMC2171	<p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1214_17_osimertinib_Tagrisso/osimertinib_Tagrisso">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1214_17_osimertinib_Tagrisso/osimertinib_Tagrisso</a></p> Monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutations	Not routinely available as not recommended for use in NHSScotland	07/10/2019
<b>Ospemifene</b> tablets  <b>Senshio®</b>  SMC2170	Treatment of moderate to severe symptomatic vulvar and vaginal atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.	Routinely available in line with national guidance	07/10/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Palbociclib</b> capsules Ibrance® SMC2149	Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant in women who have received prior endocrine therapy. In pre- or perimenopausal women, the endocrine therapy should be combined with a luteinizing hormone-releasing hormone (LHRH) agonist.	Routinely available in line with local or regional guidance	12/08/2019
<b>Palbociclib</b> capsules Ibrance® 1276/17	Treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer (refer to SMC advice for full details of indication).	Routinely available in line with local or regional guidance	11/12/2017
<b>Paliperidone palmitate</b> prolonged-release injection Trevicta® 1181/16	Maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	10/10/2016
<b>Panitumumab</b> infusion Vectibix® 439	1st line metastatic colorectal cancer in combination with either FOLFOX or FOLFIRI: - cetuximab for EGFR-expressing, RAS wild-type - panitumumab for RAS wild-type in	Routinely available in line with local or regional guidance	19/06/2017
	<a href="http://www.scottishmedicines.org.uk/files/advice/paliperidone_palmitate_Trevicta_Abb_FINAL_August_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/paliperidone_palmitate_Trevicta_Abb_FINAL_August_2016_for_website.pdf</a>		
	<a href="https://www.nice.org.uk/guidance/ta439">https://www.nice.org.uk/guidance/ta439</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Panobinostat</b> hard capsules Farydak® 1122/16	In combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including bortezomib and an immunomodulatory agent.	Routinely available in line with local or regional guidance	22/02/2016
<b>Parathyroid hormone</b> injection Natpar® 1334/18	As adjunctive treatment of adult patients with chronic hypoparathyroidism who cannot be adequately controlled with standard therapy alone.	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<b>Pasireotide</b> injection Signifor® 1311/18	Treatment of adult patients with Cushing's disease for whom surgery is not an option or for whom surgery has failed.	Not routinely available as not recommended for use in NHSScotland	26/02/2018
<b>Patiromer</b> powder for oral suspension Veltassa® 2084	The treatment of hyperkalaemia in adults	Not routinely available as not recommended for use in NHSScotland	13/08/2018

<https://www.scottishmedicines.org.uk/medicines-advice/parathyroid-hormone-natpar-nonsub-133418/>

[http://www.scottishmedicines.org.uk/files/advice/pasireotide\\_Signifor\\_Non\\_Sub\\_FINAL\\_Jan\\_2018\\_for\\_website.pdf](http://www.scottishmedicines.org.uk/files/advice/pasireotide_Signifor_Non_Sub_FINAL_Jan_2018_for_website.pdf)

<https://www.scottishmedicines.org.uk/media/3651/patiromer-sorbitex-calcium-veltassa-final-july-2018-for-website.pdf>



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Patisiran</b> infusion Onpattro® SMC2157	Treatment of hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) in adult patients with stage 1 or stage 2 polyneuropathy.	Routinely available in line with national guidance	10/06/2019
<b>Pegaspargase</b> injection/infusion Oncaspar® 1197/16	As a component of antineoplastic combination therapy in acute lymphoblastic leukaemia (ALL) in paediatric patients from birth to 18 years, and adult patients.	Routinely available in line with local or regional guidance	12/12/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1197_16_pegaspargase_Oncaspar_/pegaspargase_Oncaspar</a>		
<b>Peginterferon alfa-2a</b> injection Pegasys® 1312/18	Treatment of hepatitis B envelope antigen (HBeAg)- positive chronic hepatitis B in non-cirrhotic children and adolescents 3 years of age and older with evidence of viral replication and persistently elevated serum ALT levels.	Not routinely available as not recommended for use in NHSScotland	26/02/2018
	<a href="http://www.scottishmedicines.org.uk/files/advice/peginterferon_alfa-2a_Pegasys_Non_Sub_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/peginterferon_alfa-2a_Pegasys_Non_Sub_FINAL_Jan_2018_for_website.pdf</a>		
<b>Pegvisomant</b> injection Somavert® 158/05	Treatment of adult patients with acromegaly who have had an inadequate response to surgery and / or radiation therapy and in whom an appropriate medical treatment with somatostatin analogues did not normalise IGF-1 [insulin-like growth factor 1] concentrations or was not tolerated.	Routinely available in line with national guidance	11/12/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pembrolizumab</b> infusion Keytruda® SMC2207	In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations.	Routinely available in line with local or regional guidance	07/10/2019
<b>Pembrolizumab</b> infusion Keytruda® 1087/15	Monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults. This submission relates to use in adults previously treated with ipilimumab.	Not routinely available as not recommended for use in NHSScotland	12/12/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1087_15_pembrolizumab_Keytruda/pembrolizumab_Keytruda_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1087_15_pembrolizumab_Keytruda/pembrolizumab_Keytruda_Resub</a>		
<b>Pembrolizumab</b> infusion Keytruda® SMC2144	Monotherapy for the adjuvant treatment of adults with Stage III melanoma and lymph node involvement who have undergone complete resection.	Routinely available in line with local or regional guidance	10/06/2019
<b>Pembrolizumab</b> infusion Keytruda® 1296/18	Monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma who have failed autologous stem cell transplant and brentuximab vedotin, or who are transplant-ineligible and have failed brentuximab vedotin.	Routinely available in line with local or regional guidance	23/04/2018
	<a href="https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-chl-fullsubmission-129618/">https://www.scottishmedicines.org.uk/medicines-advice/pembrolizumab-keytruda-chl-fullsubmission-129618/</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pembrolizumab</b> infusion Keytruda® 1204/17  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1204_17_pembrolizumab_Keytruda/pembrolizumab_Keytruda">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1204_17_pembrolizumab_Keytruda/pembrolizumab_Keytruda</a>	Treatment of locally advanced or metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) and who have received at least one prior chemotherapy regimen.	Routinely available in line with local or regional guidance	20/02/2017
<b>Pembrolizumab</b> infusion Keytruda® 1339/18	As monotherapy, for the treatment of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy and whose tumours express PD-L1 with a combined positive score (CPS)≥10.	Not routinely available as not recommended for use in NHSScotland	08/10/2018
<b>Pembrolizumab</b> infusion Keytruda 1239/17  <a href="http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_June_2017_for_website.pdf</a>	As monotherapy for the first-line treatment of metastatic non-small cell lung carcinoma (NSCLC) in adults whose tumours express programmed death ligand 1 (PD-L1) with a ≥50% tumour proportion score (TPS) with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) positive tumour mutations.	Routinely available in line with local or regional guidance	28/08/2017
<b>Pembrolizumab</b> infusion Keytruda® 1291/18  <a href="http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_Jan_2018_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pembrolizumab_Keytruda_FINAL_Jan_2018_for_website.pdf</a>	Monotherapy for the treatment of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy.	Routinely available in line with local or regional guidance	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pembrolizumab</b> infusion Keytruda® SMC2187	In combination with carboplatin and either paclitaxel or nab-paclitaxel, for the first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in adults.	Routinely available in line with local or regional guidance	07/10/2019
<b>Pembrolizumab</b> infusion Keytruda® SMC2143	Monotherapy for the treatment of recurrent or metastatic head and neck squamous cell carcinoma in adults whose tumours express PD-L1 with a ≥50% TPS and progressing on or after platinum-containing chemotherapy	Not routinely available as not recommended for use in NHSScotland	10/12/2018
<b>Pembrolizumab</b> infusion Keytruda® SMC2127	In combination with pemetrexed and platinum chemotherapy, for the first-line treatment of metastatic non-squamous non-small cell lung carcinoma (NSCLC) in adults whose tumours have no EGFR or ALK positive mutations.	Not routinely available as not recommended for use in NHSScotland	25/02/2019
<b>Pentosan Polysulfate Sodium</b> capsules Elmiron® SMC2194	Treatment of bladder pain syndrome characterised by either glomerulations or Hunner's lesions in adults with moderate to severe pain, urgency and frequency of micturition.	Routinely available in line with local or regional guidance	09/12/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Perampanel</b> oral suspension</p> <p>Fycompa®</p> <p>SMC2218</p>	<p>The adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>12/08/2019</p>
<p><b>Perampanel</b> tablets</p> <p>Fycompa®</p> <p>1200/16</p>	<p>Adjunctive treatment of primary generalised tonic-clonic seizures in adult and adolescent patients from 12 years of age with idiopathic generalised epilepsy</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>10/10/2016</p>
<p><b>Perampanel</b> oral suspension</p> <p>Fycompa®</p> <p>SMC2172</p>	<p><a href="http://www.scottishmedicines.org.uk/files/advice/perampanel_Fycompa_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/perampanel_Fycompa_Non_Sub_FINAL_Sept_2016_for_website.pdf</a> for the adjunctive treatment of partial-onset seizures with or without secondarily generalised seizures in adult and adolescent patients from 12 years of age with epilepsy.</p>	<p>Routinely available in line with national guidance</p>	<p>12/08/2019</p>
<p><b>Pertuzumab</b> infusion</p> <p>Perjeta®</p> <p>SMC2119</p>	<p>In combination with trastuzumab and chemotherapy in the neoadjuvant treatment of adult patients with HER2 positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>10/12/2018</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Pertuzumab</b> infusion  Perjeta®  SMC2120</p>	<p>In combination with trastuzumab and docetaxel, in adult patients with HER2 positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti HER2 therapy or chemotherapy for their metastatic disease.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>25/02/2019</p>
<p><b>Pertuzumab</b> infusion  Perjeta®  SMC2197</p>	<p>For use in combination with trastuzumab and chemotherapy in the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>07/10/2019</p>
<p><b>Pertuzumab</b> infusion  Perjeta®  1121/16</p>	<p>In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>18/04/2016</p>
<p><b>Pertuzumab</b> infusion  Perjeta®  897/13</p>	<p>for use in combination with trastuzumab and docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>19/06/2017</p>
	<p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/Briefing_note_pertuzumab_Perjeta</a></p>		
	<p><a href="http://www.scottishmedicines.org.uk/files/advice/pertuzumab_Perjeta_2nd_Resub_FINAL_May_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/pertuzumab_Perjeta_2nd_Resub_FINAL_May_2017_for_website.pdf</a></p>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Pertuzumab</b> infusion</p> <p>Perjeta®</p> <p>1121/16</p>	<p>In combination with trastuzumab and chemotherapy for the neoadjuvant treatment of adult patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/pertuzumab_Perjeta_Resub">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1121_16_pertuzumab_Perjeta/pertuzumab_Perjeta_Resub</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>12/12/2016</p>
<p><b>Phenylephrine hydrochloride, tropicamide</b> ophthalmic insert</p> <p>Mydriaser®</p> <p>Formulary appeal</p>	<p>For use in adult patients to obtain pre-operative mydriasis or for diagnostic purposes when monotherapy is known to be insufficient.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>18/04/2016</p>
<p><b>Pitolisant</b> tablets</p> <p>Wakix®</p> <p>1229/17</p>	<p>Treatment of narcolepsy with or without cataplexy in adults</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1229_17_pitolisant_Wakix/pitolisant_Wakix">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1229_17_pitolisant_Wakix/pitolisant_Wakix</a></p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>20/02/2017</p>
<p><b>Pixantrone</b> infusion</p> <p>Pixuvri®</p> <p>1138/16</p>	<p>Monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive Non Hodgkin B-cell Lymphomas</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>22/02/2016</p>

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Pomalidomide</b> capsules Imnovid® SMC2219	In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior treatment regimen including lenalidomide.	Not routinely available as not recommended for use in NHSScotland	12/08/2019
<b>Prasterone</b> pessary Intrarosa® SMC2255	Treatment of vulvar and vaginal atrophy in postmenopausal women having moderate to severe symptoms.	Not routinely available as not recommended for use in NHSScotland	09/12/2019
<b>Prednisolone</b> rectal foam Predfoam® and generic N/A	Treatment of inflammatory bowel conditions	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	28/08/2017
<b>Progesterone</b> injection Lubion® SMC2017	In adults for luteal support as part of an Assisted Reproductive Technology (ART) treatment program in infertile women who are unable to use or tolerate vaginal preparations.	Routinely available in line with national guidance	13/08/2018
	<a href="https://www.scottishmedicines.org.uk/media/3560/progesterone-lubion-abbreviated-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3560/progesterone-lubion-abbreviated-final-june-2018-for-website.pdf</a>		



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Progesterone</b> vaginal tablets Lutigest® 1185/16  <a href="http://www.scottishmedicines.org.uk/files/advice/progesterone_Lutigest_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/progesterone_Lutigest_FINAL_Sept_2016_for_website.pdf</a>	Luteal support as part of an assisted reproductive technology (ART) treatment program for infertile women	Routinely available in line with national guidance	10/10/2016
<b>Raltegravir</b> tablets Isentress® 1280/17	In combination with other anti-retroviral medicinal products for the treatment of human immunodeficiency virus (HIV-1) infection in adults and paediatric patients weighing at least 40kg.	Routinely available in line with national guidance	11/12/2017
<b>Raltegravir</b> oral suspension Isentress® SMC2101  <a href="https://www.scottishmedicines.org.uk/medicines-advice/raltegravir-isentress-non-submission-smc2101/">https://www.scottishmedicines.org.uk/medicines-advice/raltegravir-isentress-non-submission-smc2101/</a>	In combination with other anti-retroviral medicinal products in the treatment of human immunodeficiency virus in neonates.	Not routinely available as not recommended for use in NHSScotland	13/08/2018
<b>Ramucirumab</b> infusion Cymaza® 1165/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1165_16_ramucirumab_Cyramza/ramucirumb_Cyramza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1165_16_ramucirumab_Cyramza/ramucirumb_Cyramza</a>	In combination with docetaxel for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with disease progression after platinum-based chemotherapy.	Not routinely available as not recommended for use in NHSScotland	13/06/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ramucirumab</b> infusion Cyramza® SMC2246	As monotherapy for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha fetoprotein of $\geq 400$ ng/mL and who have been previously treated with sorafenib.	Not routinely available as not recommended for use in NHSScotland	09/12/2019
<b>Ramucirumab</b> infusion Cyrmaza® 1156/16	In combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) for the treatment of adult patients with metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin and a fluoropyrimidine	Not routinely available as not recommended for use in NHSScotland	13/06/2016
<b>Ramucirumab</b> infusion Cyramza® 1176/16	<ul style="list-style-type: none"> <li>- In combination with paclitaxel for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum and fluoropyrimidine chemotherapy</li> <li>- As monotherapy for the treatment of adult patients with advanced gastric cancer or gastro-oesophageal junction adenocarcinoma with disease progression after prior platinum or fluoropyrimidine chemotherapy, for whom treatment in combination with paclitaxel is not appropriate</li> </ul>	Not routinely available as not recommended for use in NHSScotland	22/08/2016
	<a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1176_16_ramucirumab_Cyramza/ramucirumab_Cyramza">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1176_16_ramucirumab_Cyramza/ramucirumab_Cyramza</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ranibizumab</b> injection Lucentis® SMC2274	In preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 3+) or AP-ROP (aggressive posterior ROP) disease.	Not routinely available as not recommended for use in NHSScotland	06/07/2020
<b>Ranibizumab</b> injection Lucentis® SMC2270	Treatment of proliferative diabetic retinopathy in adults.	Not routinely available as not recommended for use in NHSScotland	24/02/2020
<b>Regorafenib</b> tablets Stivarga® 1316/18	Monotherapy for the treatment of adult patients with hepatocellular carcinoma who have been previously treated with sorafenib.	Routinely available in line with local or regional guidance	11/06/2018
<b>Reslizumab</b> infusion Cinqaero® 1233/17	As add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.	Not routinely available as not recommended for use in NHSScotland	11/12/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ribociclib</b> film-coated tablets Kisqali® 1295/18	In combination with an aromatase inhibitor, for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.  <a href="https://www.scottishmedicines.org.uk/medicines-advice/ribociclib-kisqali-fullsubmission-129518/">https://www.scottishmedicines.org.uk/medicines-advice/ribociclib-kisqali-fullsubmission-129518/</a>	Routinely available in line with local or regional guidance	23/04/2018
<b>Ribociclib</b> tablet Kisqali® SMC2198	Treatment of women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer in combination with fulvestrant* as initial endocrine-based therapy, or in women who have received prior endocrine therapy.	Routinely available in line with local or regional guidance	09/12/2019
<b>Rilpivirine</b> tablet Edurant® 1168/16	In combination with other antiretroviral medicinal products, for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in antiretroviral treatment-naïve patients aged 12 to 18 years of age and older with a viral load (VL) ≤ 100,000 HIV-1 RNA copies/mL.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1168_16_rilpivirine_hydrochloride_Edurant/rilpivirine_hydrochloride_Edurant">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1168_16_rilpivirine_hydrochloride_Edurant/rilpivirine_hydrochloride_Edurant</a>	Routinely available in line with national guidance	22/08/2016
<b>Rilpivirine, Emtricitabine, Tenofovir alafenamide</b> tablets Odefsey® 1189/16	Treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg), infected with human immunodeficiency virus type 1 (HIV 1) without known mutations associated with resistance to the non nucleoside reverse transcriptase inhibitor (NNRTI) class, tenofovir or emtricitabine, and with viral load HIV 1 RNA ≤100,000 copies/mL.  <a href="http://www.scottishmedicines.org.uk/files/advice/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/rilpivirine_emtricitabine_Odefsey_Abbreviated_FINAL_Sept_2016_for_website.pdf</a>	Routinely available in line with national guidance	10/10/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Risankizumab</b> injection Skyrizi® SMC2196	The treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.	Routinely available in line with national guidance	09/12/2019
		31/12/2019	
<b>Rituximab</b> infusion MabThera® SMC2165	In combination with glucocorticoids, for the treatment of adult patients with severe, active granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA).	Not routinely available as not recommended for use in NHSScotland	29/04/2019
<b>Rituximab</b> infusion MabThera® SMC2193	Treatment of patients with moderate to severe pemphigus vulgaris.	Not routinely available as not recommended for use in NHSScotland	10/06/2019
<b>Rivaroxaban</b> tablet Xarelto® SMC2128	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with coronary artery disease at high risk of ischaemic events	Routinely available in line with local or regional guidance	25/02/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Roflumilast</b> tablets <b>Daxas®</b> 635/10	<p>For maintenance treatment of severe chronic obstructive pulmonary disease (COPD) (forced expiratory volume in one second [FEV1]) post-bronchodilator less than 50% predicted) associated with chronic bronchitis in adult patients with a history of frequent exacerbations as add on to bronchodilator treatment</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/roflumilast_Daxas_Resubmission_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/roflumilast_Daxas_Resubmission_FINAL_August_2017_for_website.pdf</a></p>	Not routinely available as not recommended for use in NHSScotland	23/10/2017
<b>Rolapitant</b> tablets <b>Varuby®</b> 1266/17	<p>Prevention of delayed nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in adults. Rolapitant is given as part of combination therapy.</p> <p><a href="http://www.scottishmedicines.org.uk/files/advice/rolapitant_Varuby_FINAL_August_2017_amended_030917_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/rolapitant_Varuby_FINAL_August_2017_amended_030917_for_website.pdf</a></p>	Routinely available in line with local or regional guidance	23/10/2017
<b>Romiplostim</b> injection <b>Nplate®</b> SMC2126	<p>Chronic immune (idiopathic) thrombocytopenic purpura (ITP) patients one year of age and older who are refractory to other treatments (e.g. corticosteroids, immunoglobulins)</p>	Routinely available in line with national guidance	29/04/2019
<b>Rucaparib</b> tablets <b>Rubraca®</b> SMC2224	<p>As monotherapy for the maintenance treatment of adult patients with platinum-sensitive relapsed high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete or partial) to platinum-based chemotherapy.</p>	Routinely available in line with local or regional guidance	06/07/2020

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Rucaparib</b> tablets <b>Rubraca®)</b> SMC2221	as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy.	Not routinely available as not recommended for use in NHSScotland	12/08/2019
<b>Rufinamide</b> suspension, tablets <b>Inovelon®)</b> SMC2146	As adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients 1 years to $\leq 4$ years.	Routinely available in line with national guidance	29/04/2019
<b>Ruxolitinib</b> tablets <b>Jakavi®)</b> SMC2213	The treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea (hydroxycarbamide).	Routinely available in line with local or regional guidance	09/12/2019
<b>Ruxolitinib phosphate</b> tablets <b>Jakavi®)</b> 1166/16	Treatment of adult patients with polycythaemia vera who are resistant to or intolerant of hydroxyurea.	Not routinely available as not recommended for use in NHSScotland	13/06/2016

[http://www.scottishmedicines.org.uk/SMC\\_Advice/Advice/1166\\_16\\_ruxolitinib\\_as\\_phosphate\\_Jakavi/ruxolitinib\\_Jakavi\\_Non\\_submission](http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1166_16_ruxolitinib_as_phosphate_Jakavi/ruxolitinib_Jakavi_Non_submission)

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Sacubitril/Valsartan</b> film coated tablets  <b>Entresto®</b>  1132/16  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1132_16_sacubitril_valsartan_Entresto/Briefing_note_sacubitril_valsartan_Entresto">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1132_16_sacubitril_valsartan_Entresto/Briefing_note_sacubitril_valsartan_Entresto</a>	In adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.	Routinely available in line with local or regional guidance	18/04/2016
<b>Safinamide</b> tablets  <b>Xadago®</b>  1259/17  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1259_17_safinamide_Xadago/safinamide_Xadago_Non-submission">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1259_17_safinamide_Xadago/safinamide_Xadago_Non-submission</a>	Treatment of adult patients with idiopathic Parkinson's disease (PD) as add-on therapy to a stable dose of Levodopa alone or in combination with other PD medicinal products in mid-to late-stage fluctuating patients.	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Sapropterin Dihydrochloride</b> soluble tablets  <b>Kuvan®</b>  558/09  <a href="https://www.scottishmedicines.org.uk/media/3652/sapropterin-kuvan-final-july-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3652/sapropterin-kuvan-final-july-2018-for-website.pdf</a>	The treatment of hyperphenylalaninaemia (HPA) in adults and paediatric patients of all ages with phenylketonuria (PKU) who have been shown to be responsive to such treatment.	Not routinely available as not recommended for use in NHSScotland	13/08/2018
<b>Sarilumab</b> sub-cutaneous injection  <b>Kevzara®</b>  1314/18  <a href="https://www.scottishmedicines.org.uk/medicines-advice/sarilumab-kevzara-fullsubmission-131418/">https://www.scottishmedicines.org.uk/medicines-advice/sarilumab-kevzara-fullsubmission-131418/</a>	In combination with methotrexate for the treatment of moderately to severely active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Sarilumab can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.	Routinely available in line with local or regional guidance	23/04/2018



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Saxagliptin with Dapagliflozin</b> tablets Qtern 1255/17	in adults aged 18 years and older with type 2 diabetes mellitus 1)to improve glycaemic control when metformin and/or sulphonylurea and one of the monocomponents of Qtern® do not provide adequate glycaemic control or 2) when already being treated with the free combination of dapagliflozin and saxagliptin  <a href="http://www.scottishmedicines.org.uk/files/advice/saxagliptin-dapagliflozin_Qtern_Abbreviated_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/saxagliptin-dapagliflozin_Qtern_Abbreviated_FINAL_June_2017_for_website.pdf</a>	Routinely available in line with national guidance	28/08/2017
<b>Secukinumab</b> sub-cutaneous injection Cosentyx® 1159/16	Treatment of active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1159_16_secukinumab_Cosentyx_AS/secukinumab_Cosentyx">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1159_16_secukinumab_Cosentyx_AS/secukinumab_Cosentyx</a>	Routinely available in line with national guidance	22/08/2016
<b>Secukinumab</b> sub-cutaneous injection Cosentyx® 1167/16	alone or in combination with methotrexate, for the treatment of active psoriatic arthritis in adult patients when the response to previous disease-modifying anti-rheumatic drug (DMARD) therapy has been inadequate.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1167_16_secukinumab_Cosentyx/secukinumab_Cosentyx">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1167_16_secukinumab_Cosentyx/secukinumab_Cosentyx</a>	Routinely available in line with national guidance	22/08/2016
<b>Selexipag</b> tablets Uptravi® 1235/17	Long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II to III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies.	Routinely available in line with national guidance	11/06/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Selexipag</b> tablets <b>Uptravi</b> 1235/17	For the long-term treatment of pulmonary arterial hypertension (PAH) in adult patients with WHO functional class (FC) II to III, either as combination therapy in patients insufficiently controlled with an endothelin receptor antagonist (ERA) and/or a phosphodiesterase type 5 (PDE-5) inhibitor, or as monotherapy in patients who are not candidates for these therapies  <a href="http://www.scottishmedicines.org.uk/files/advice/selexipag_Uptravi_FINAL_June_2017_for_website_amended_10.08.17.pdf">http://www.scottishmedicines.org.uk/files/advice/selexipag_Uptravi_FINAL_June_2017_for_website_amended_10.08.17.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Semaglutide</b> injection in pre-filled pen <b>Ozempic®</b> SMC2092	Treatment of adults with insufficiently controlled type 2 diabetes mellitus (T2DM) as an adjunct to diet and exercise: - As monotherapy when metformin is considered inappropriate due to intolerance or contraindications - In addition to other medicinal products for the treatment of diabetes.	Routinely available in line with national guidance	25/02/2019
<b>Sevelamer carbonate</b> oral suspension <b>Renvela®</b> 1304/18	Control of hyperphosphataemia in paediatric patients (>6 years of age and a Body Surface Area of >0.75m <sup>2</sup> ) with chronic kidney disease.	Routinely available in line with national guidance	12/02/2018
<b>Sirolimus</b> tablets, solution <b>Rapamune®</b> SMC2173	Treatment of patients with sporadic lymphangioleiomyomatosis with moderate lung disease or declining lung function	Not routinely available as not recommended for use in NHSScotland	08/10/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Sodium Zirconium Cyclosilicate</b> suspension Lokelma® SMC2233	treatment of hyperkalaemia in adult patients	Not routinely available as not recommended for use in NHSScotland	24/02/2020
<b>Sofosbuvir</b> tablets Sovaldi ® 1326/18	In combination with other medicinal products for the treatment of chronic hepatitis C in adolescents aged 12 to <18 years.	Not routinely available as not recommended for use in NHSScotland	23/04/2018
<b>Sofosbuvir and Velpatasvir</b> tablets Epclusa® 1195/16	Treatment of chronic hepatitis C virus (HCV) infection in adults.  <a href="https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvir-400mg-film-coated-tablets-sovaldi-non-submission-132618/">https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvir-400mg-film-coated-tablets-sovaldi-non-submission-132618/</a>	Routinely available in line with national guidance	12/12/2016
<b>Sofosbuvir and Velpatasvir</b> tablets Epclusa® 1271/17	Treatment of chronic hepatitis C virus (HCV) infection in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1195_16_sofosbuvir_velpatasvir_Epclusa/sofosbuvir_velpatasvir_Epclusa</a>	Routinely available in line with local or regional guidance	23/04/2018
	<a href="https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvir-epclusa-fullsubmission-127117/">https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvir-epclusa-fullsubmission-127117/</a>		

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Sofosbuvir with Velpatasvir</b> tablets Eplclusa® 1271/17  <a href="http://www.scottishmedicines.org.uk/files/advice/sofosbuvir_velpatasvir_Eplclusa_FINAL_Sept_2017_05.10.17_amended_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/sofosbuvir_velpatasvir_Eplclusa_FINAL_Sept_2017_05.10.17_amended_for_website.pdf</a>	Treatment of chronic hepatitis C virus (HCV) infection in adults	Routinely available in line with national guidance	23/10/2017
<b>Sofosbuvir, Velpatasvir and Voxilaprevir</b> tablets Vosevi® 1317/18  <a href="https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvirvoxilaprevir-vosevi-fullsubmission-131718/">https://www.scottishmedicines.org.uk/medicines-advice/sofosbuvirvelpatasvirvoxilaprevir-vosevi-fullsubmission-131718/</a>	Treatment of chronic hepatitis C virus (HCV) infection in adults.	Routinely available in line with national guidance	23/04/2018
<b>Sorafenib</b> tablets Nexavar® 482/08	Treatment of hepatocellular carcinoma	Routinely available in line with local or regional guidance	22/02/2016
<b>Stiripentol</b> capsules, suspension sachet Diacomit® 524/08  <a href="http://www.scottishmedicines.org.uk/files/advice/stiripentol_Diacomit_Resubmission_FINAL_August_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/stiripentol_Diacomit_Resubmission_FINAL_August_2017_for_website.pdf</a>	In conjunction with clobazam and valproate as adjunctive therapy of refractory generalised tonic-clonic seizures in patients with severe myoclonic epilepsy in infancy (SMEI; Dravet's syndrome) whose seizures are not adequately controlled with clobazam and valproate.	Routinely available in line with national guidance	23/10/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Sufentanil citrate</b> sublingual tablets Zalviso® 1270/17	Management of acute moderate to severe post-operative pain in adult patients.  <a href="http://www.scottishmedicines.org.uk/files/advice/sufentanil_Zalviso_Non_Sub_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/sufentanil_Zalviso_Non_Sub_FINAL_July_2017_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<b>Talimogene laherparepvec</b> injection Imlygic® 1248/17	Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1248_17_talimogene_laherparepvec_Imlygic/talimogene_laherparepvec_Imlygic_Non_S">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1248_17_talimogene_laherparepvec_Imlygic/talimogene_laherparepvec_Imlygic_Non_S</a>	Not routinely available as not recommended for use in NHSScotland	19/06/2017
<b>Teduglutide</b> injection Revestive® 1139/16	Treatment of patients aged one year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.	Routinely available in line with national guidance	23/04/2018
<b>Teduglutide</b> injection Revestive® SMC2225	for the treatment of patients age 1 year and above with short bowel syndrome (SBS). Patients should be stable following a period of intestinal adaptation after surgery.	Routinely available in line with local or regional guidance	24/02/2020

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Teduglutide</b> injection Revestive® 1139/16	Treatment of adult patients with Short Bowel Syndrome	Not routinely available as not recommended for use in NHSScotland	22/02/2016
<b>Telotristat</b> tablets Xermelo® 1327/18	Treatment of carcinoid syndrome diarrhoea in combination with somatostatin analogue therapy in adults inadequately controlled by somatostatin analogue therapy.	Routinely available in line with local or regional guidance	11/06/2018
<b>Tenofovir alafenamide</b> tablets Vemlidy® 1238/17	Treatment of chronic hepatitis B in adults and adolescents (aged 12 years and older with body weight at least 35 kg).	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Testosterone</b> transdermal gel Testavan® SMC2152	Testosterone replacement therapy for adult male hypogonadism, when testosterone deficiency has been confirmed by clinical features and biochemical tests.  <a href="http://www.scottishmedicines.org.uk/files/advice/tenofovir_alafenamide_Vemlidy_Non_Sub_FINAL_March_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/tenofovir_alafenamide_Vemlidy_Non_Sub_FINAL_March_2017_for_website.pdf</a>	Routinely available in line with national guidance	29/04/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Tezacaftor and Ivacaftor</b> tablets Symkevi SMC2183	In a combination regimen with ivacaftor 150mg tablets for the treatment of patients with cystic fibrosis (CF) aged 12 years and older who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3A→G, S945L, S977F, R1070W, D1152H, 2789+5G→A, 3272-26A→G, and 3849+10kbC→T.	Not routinely available as not recommended for use in NHSScotland	12/08/2019
<b>Ticagrelor</b> tablets Brilique® 1224/17	Co-administered with acetylsalicylic acid for the prevention of atherothrombotic events in adult patients with a history of myocardial infarction and a high risk of developing an atherothrombotic event.	Not routinely available as not recommended for use in NHSScotland	24/04/2017
<b>Tildrakizumab</b> injection Ilumetri® SMC2167	The treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.	Routinely available in line with national guidance  31/12/2019	09/12/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Tiotropium</b> Solution for inhalation <b>Spiriva Respimat®</b>  411/07</p>	<p>As a maintenance bronchodilator treatment to relieve symptoms of patients with chronic obstructive pulmonary disease (COPD).</p>	<p>Routinely available in line with national guidance</p>	<p>11/12/2017</p>
<p><b>Tiotropium</b> solution for inhalation <b>Spiriva® Respimat®</b>  SMC2118</p>	<p>Add-on maintenance bronchodilator treatment in patients aged 6 years and older with severe asthma who experienced one or more severe asthma exacerbations in the preceding year.</p>	<p>Routinely available in line with national guidance</p>	<p>25/02/2019</p>
<p><b>Tisagenlecleucel</b> infusion <b>Kymriah®</b>  SMC2200</p>	<p>Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.</p>	<p>Routinely available in line with local or regional guidance</p>	<p>07/10/2019</p>
<p><b>Tisagenlecleucel</b> infusion <b>Kymriah®</b>  SMC2141</p>	<p>For adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.</p>	<p>Not routinely available as not recommended for use in NHSScotland</p>	<p>29/04/2019</p>



Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Tivozanib</b> capsules <b>Fotivda®</b> 1335/18	First-line treatment of adult patients with advanced renal cell carcinoma and for adult patients who are vascular endothelial growth factor receptor and mammalian target of rapamycin pathway inhibitor-naïve following disease progression after one prior treatment with cytokine therapy for advanced renal cell carcinoma (RCC).  <a href="https://www.scottishmedicines.org.uk/media/3562/tivozanib-fotivda-final-june-2018-for-website.pdf">https://www.scottishmedicines.org.uk/media/3562/tivozanib-fotivda-final-june-2018-for-website.pdf</a>	Routinely available in line with local or regional guidance	13/08/2018
<b>Tocilizumab</b> injection <b>RoActemra®</b> 1201/16	Treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.  <a href="http://www.scottishmedicines.org.uk/files/advice/tocilizumab_RoActemra_Non_Sub_FINAL_Sept_2016_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/tocilizumab_RoActemra_Non_Sub_FINAL_Sept_2016_for_website.pdf</a>	Not routinely available as not recommended for use in NHSScotland	10/10/2016
<b>Tocilizumab</b> subcutaneous injection <b>RoActemra®</b> SMC2014	The treatment of Giant Cell Arteritis (GCA) in adult patients	Routinely available in line with local or regional guidance	07/10/2019
<b>Tofacitinib</b> tablets <b>Xeljanz®</b> 1298/18	In combination with methotrexate for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more DMARDs. Tofacitinib can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.  <a href="http://www.scottishmedicines.org.uk/files/advice/tofacitinib_Xeljanz_FINAL_Jan_2018_Amended_05.02.17_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/tofacitinib_Xeljanz_FINAL_Jan_2018_Amended_05.02.17_for_website.pdf</a>	Routinely available in line with local or regional guidance	26/02/2018

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Tofacitinib</b> tablets Xeljanz® SMC2122	Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.	Routinely available in line with local or regional guidance	25/02/2019
<b>Tofacitinib</b> tablet Xeljanz® SMC2116	In combination with methotrexate for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy.	Routinely available in line with local or regional guidance	25/02/2019
<b>Tolvaptan</b> tablets Jinarc® 1114/15	To slow the progression of cyst development and renal insufficiency of autosomal dominant polycystic kidney disease (ADPKD) in adults with chronic kidney disease stage 1 to 3 at initiation of treatment with evidence of rapidly progressing disease.	Routinely available in line with national guidance	22/02/2016
<b>Topotecan, Caelyx, paclitaxel, trabectedin, gemcitabine</b>	Recurrent ovarian cancer	Routinely available in line with national guidance	13/06/2016
NICE MTA 389  <a href="https://www.nice.org.uk/guidance/ta389">https://www.nice.org.uk/guidance/ta389</a>			

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Trabectedin</b> infusion Yondelis® SMC2210	The treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents.	Not routinely available as not recommended for use in NHSScotland	09/12/2019
<b>Trametinib</b> tablets Mekinist® 1161/16	In combination with dabrafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation	Routinely available in line with local or regional guidance	10/10/2016
<a href="http://www.scottishmedicines.org.uk/files/advice/trametinib_0_5mg_and_2mg_Mekinist_FINAL_August_2016_Amended_02.09.16_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/trametinib_0_5mg_and_2mg_Mekinist_FINAL_August_2016_Amended_02.09.16_for_website.pdf</a>			
<b>Trametinib (with dabrafenib)</b> tablets Mekinist® 1264/17	in combination with dabrafenib for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation	Not routinely available as not recommended for use in NHSScotland	28/08/2017
<a href="http://www.scottishmedicines.org.uk/files/advice/trametinib_Mekinist_Non_Submission_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/trametinib_Mekinist_Non_Submission_FINAL_June_2017_for_website.pdf</a>			
<b>Trastuzumab emtansine</b> infusion Kadcyla® 990/14	As a single agent, for the treatment of adult patients with human epidermal growth factor type 2 (HER2)-positive, unresectable locally advanced or metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Patients should have either received prior therapy for locally advanced or metastatic disease, or developed disease recurrence during or within six months of completing adjuvant therapy.	Routinely available in line with local or regional guidance	24/04/2017

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Trientine tetrahydrochloride</b> tablet Cuprior® SMC2222	Treatment of Wilson's disease in adults, adolescents and children ≥5 years intolerant to D-penicillamine therapy	Routinely available in line with national guidance	09/12/2019
<b>Trifluridine/tipiracil hydrochloride</b> tablets Lonsurf® 1221/17	Treatment of adult patients with metastatic colorectal cancer (CRC) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti vascular endothelial growth factor agents, and anti-epidermal growth factor receptor agents.	Routinely available in line with local or regional guidance	20/02/2017
<b>Triptorelin</b> sustained-release injection Decapeptyl SR® SMC2186	<p>As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as premenopausal after completion of chemotherapy.</p> <p><a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1221_17_trifluridine_tipiracil_as_hydrochloride_Lonsurf/trifluridine_tipiracil_as_hydrochloride">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1221_17_trifluridine_tipiracil_as_hydrochloride_Lonsurf/trifluridine_tipiracil_as_hydrochloride</a></p>	Routinely available in line with local or regional guidance	07/10/2019
<b>Ulipristal acetate</b> tablet Esmya® 1128/16	Intermittent treatment of moderate to severe symptoms of uterine fibroids in adult women of reproductive age.	Routinely available in line with national guidance	22/02/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Ustekinumab</b> infusion, injection Stelara® SMC2250	Treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a biologic or have medical contraindications to such therapies.	Routinely available in line with national guidance	06/07/2020
<b>Ustekinumab</b> injection and prefilled syringe Stelara® 1115/15	Treatment of moderate to severe plaque psoriasis in adolescent patients from the age of 12 years and older, who are inadequately controlled by, or are intolerant to, other systemic therapies or phototherapies.	Routinely available in line with national guidance	22/02/2016
<b>Ustekinumab</b> infusion, injection Stelara® 1250/17	for the treatment of adult patients with moderately to severely active Crohn's disease who have had an inadequate response with, lost response to, or were intolerant to either conventional therapy or a tumour necrosis factor-alpha (TNF $\alpha$ ) antagonist or have medical contraindications to such therapies.  <a href="http://www.scottishmedicines.org.uk/files/advice/ustekinumab_Stelara_FINAL_June_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/ustekinumab_Stelara_FINAL_June_2017_for_website.pdf</a>	Routinely available in line with national guidance	28/08/2017
<b>Venetoclax</b> tablets Venclyxto® SMC2166	in combination with rituximab for the treatment of adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy.	Routinely available in line with local or regional guidance	12/08/2019

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<b>Venetoclax</b> tablets <b>Venclyxto®</b> 1249/17	as monotherapy for the treatment of chronic lymphocytic leukaemia (CLL) either in the presence of 17p deletion or TP53 mutation in adult patients who are unsuitable for or have failed a B-cell receptor pathway inhibitor, or in the absence of 17p deletion or TP53 mutation in adult patients who have failed both chemoimmunotherapy and a B-cell receptor pathway inhibitor.  <a href="http://www.scottishmedicines.org.uk/files/advice/venetoclax_Venclyxto_FINAL_July_2017_for_website.pdf">http://www.scottishmedicines.org.uk/files/advice/venetoclax_Venclyxto_FINAL_July_2017_for_website.pdf</a>	Routinely available in line with local or regional guidance	28/08/2017
<b>Vernakalant</b> infusion <b>Brinavess®</b> 1222/17	Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults - For non-surgery patients: atrial fibrillation ≤ 7 days duration - For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1222_17_vernakalant_Brinavess/vernakalant_Brinavess">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1222_17_vernakalant_Brinavess/vernakalant_Brinavess</a>	Not routinely available as not recommended for use in NHSScotland	20/02/2017
<b>Vortioxetine</b> tablets <b>Brintellix®</b> 1158/16	Treatment of major depressive episodes in adults.  <a href="http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1158_16_vortioxetine_Brintellix/vortioxetine_Brintellix">http://www.scottishmedicines.org.uk/SMC_Advice/Advice/1158_16_vortioxetine_Brintellix/vortioxetine_Brintellix</a>	Not routinely available as local clinical experts do not wish to add the medicine to the Formulary at this time or there is a local preference for alternative medicine(s)	22/08/2016

Medicine	Condition being treated	NHSGGC Decision	Date of decision
<p><b>Zanamivir</b> infusion</p> <p><b>Dectova®</b></p> <p>SMC2204</p>	<p>Treatment of complicated and potentially life-threatening influenza A or B virus infection in adult and paediatric patients (aged ≥ 6 months) when:</p> <ul style="list-style-type: none"> <li>- the patient's influenza virus is known or suspected to be resistant to anti-influenza medicinal products other than zanamivir, and/or</li> <li>- other anti-viral medicinal products for treatment of influenza, including inhaled zanamivir, are not suitable for the individual patient.</li> </ul>	<p>Routinely available in line with national guidance</p>	<p>09/12/2019</p>